JP2017518348A - Irak4阻害剤としての置換インダゾール化合物 - Google Patents
Irak4阻害剤としての置換インダゾール化合物 Download PDFInfo
- Publication number
- JP2017518348A JP2017518348A JP2016574004A JP2016574004A JP2017518348A JP 2017518348 A JP2017518348 A JP 2017518348A JP 2016574004 A JP2016574004 A JP 2016574004A JP 2016574004 A JP2016574004 A JP 2016574004A JP 2017518348 A JP2017518348 A JP 2017518348A
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- mmol
- disease
- compound
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title claims abstract description 5
- 229940127590 IRAK4 inhibitor Drugs 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 78
- 201000010099 disease Diseases 0.000 claims abstract description 51
- 150000003839 salts Chemical class 0.000 claims abstract description 43
- 208000035475 disorder Diseases 0.000 claims abstract description 27
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims abstract description 13
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims abstract description 13
- 150000001875 compounds Chemical class 0.000 claims description 303
- -1 Benzotriazinyl Chemical group 0.000 claims description 210
- 238000000034 method Methods 0.000 claims description 72
- 125000000217 alkyl group Chemical group 0.000 claims description 41
- 239000003814 drug Substances 0.000 claims description 38
- 125000000623 heterocyclic group Chemical group 0.000 claims description 36
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 201000011510 cancer Diseases 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 26
- 238000011282 treatment Methods 0.000 claims description 24
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 22
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 21
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000003118 aryl group Chemical group 0.000 claims description 18
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 16
- 208000027866 inflammatory disease Diseases 0.000 claims description 15
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 15
- 230000001404 mediated effect Effects 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000003107 substituted aryl group Chemical group 0.000 claims description 14
- 125000002252 acyl group Chemical group 0.000 claims description 13
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims description 13
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims description 11
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 11
- 208000030159 metabolic disease Diseases 0.000 claims description 11
- 125000002971 oxazolyl group Chemical group 0.000 claims description 11
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 11
- 208000020084 Bone disease Diseases 0.000 claims description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 229940088597 hormone Drugs 0.000 claims description 10
- 239000005556 hormone Substances 0.000 claims description 10
- 230000007170 pathology Effects 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 208000026350 Inborn Genetic disease Diseases 0.000 claims description 9
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 108090000190 Thrombin Proteins 0.000 claims description 9
- 230000030833 cell death Effects 0.000 claims description 9
- 230000001066 destructive effect Effects 0.000 claims description 9
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 9
- 208000016361 genetic disease Diseases 0.000 claims description 9
- 208000019423 liver disease Diseases 0.000 claims description 9
- 125000004193 piperazinyl group Chemical group 0.000 claims description 9
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims description 9
- 229960004072 thrombin Drugs 0.000 claims description 9
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 125000002393 azetidinyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000002541 furyl group Chemical group 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 7
- 125000002757 morpholinyl group Chemical group 0.000 claims description 7
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 7
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 7
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000001544 thienyl group Chemical group 0.000 claims description 7
- 125000001425 triazolyl group Chemical group 0.000 claims description 7
- BPMFPOGUJAAYHL-UHFFFAOYSA-N 9H-Pyrido[2,3-b]indole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=N1 BPMFPOGUJAAYHL-UHFFFAOYSA-N 0.000 claims description 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 6
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 6
- 206010047115 Vasculitis Diseases 0.000 claims description 6
- 230000007815 allergy Effects 0.000 claims description 6
- 125000004988 dibenzothienyl group Chemical group C1(=CC=CC=2SC3=C(C21)C=CC=C3)* 0.000 claims description 6
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims description 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 5
- 208000033065 inborn errors of immunity Diseases 0.000 claims description 5
- 201000008383 nephritis Diseases 0.000 claims description 5
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims description 5
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims description 5
- 210000003491 skin Anatomy 0.000 claims description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 5
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims description 4
- 208000015943 Coeliac disease Diseases 0.000 claims description 4
- 206010010741 Conjunctivitis Diseases 0.000 claims description 4
- 201000005569 Gout Diseases 0.000 claims description 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims description 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 201000002481 Myositis Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 206010033645 Pancreatitis Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 206010035664 Pneumonia Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 4
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 230000001363 autoimmune Effects 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 4
- 201000001981 dermatomyositis Diseases 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 4
- 125000001041 indolyl group Chemical group 0.000 claims description 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 125000003566 oxetanyl group Chemical group 0.000 claims description 4
- 230000036407 pain Effects 0.000 claims description 4
- 210000002307 prostate Anatomy 0.000 claims description 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000009890 sinusitis Diseases 0.000 claims description 4
- 125000005415 substituted alkoxy group Chemical group 0.000 claims description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
- 125000001984 thiazolidinyl group Chemical group 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
- 208000019758 Hypergammaglobulinemia Diseases 0.000 claims description 3
- 208000029462 Immunodeficiency disease Diseases 0.000 claims description 3
- 101150053046 MYD88 gene Proteins 0.000 claims description 3
- 102100024134 Myeloid differentiation primary response protein MyD88 Human genes 0.000 claims description 3
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 201000010105 allergic rhinitis Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 claims description 3
- 208000030533 eye disease Diseases 0.000 claims description 3
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims description 3
- 208000019622 heart disease Diseases 0.000 claims description 3
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 3
- 208000032839 leukemia Diseases 0.000 claims description 3
- 210000004185 liver Anatomy 0.000 claims description 3
- 210000004072 lung Anatomy 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- 125000000160 oxazolidinyl group Chemical group 0.000 claims description 3
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims description 3
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- GVIJJXMXTUZIOD-UHFFFAOYSA-N thianthrene Chemical compound C1=CC=C2SC3=CC=CC=C3SC2=C1 GVIJJXMXTUZIOD-UHFFFAOYSA-N 0.000 claims description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims description 2
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 208000003200 Adenoma Diseases 0.000 claims description 2
- 206010001233 Adenoma benign Diseases 0.000 claims description 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims description 2
- 206010001889 Alveolitis Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 206010003011 Appendicitis Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010006811 Bursitis Diseases 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims description 2
- 208000006029 Cardiomegaly Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 241001317099 Dystaxia Species 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000004145 Endometritis Diseases 0.000 claims description 2
- 208000004232 Enteritis Diseases 0.000 claims description 2
- 201000011275 Epicondylitis Diseases 0.000 claims description 2
- 206010016228 Fasciitis Diseases 0.000 claims description 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims description 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims description 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 2
- 208000007882 Gastritis Diseases 0.000 claims description 2
- 208000005577 Gastroenteritis Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 208000022461 Glomerular disease Diseases 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims description 2
- 206010062639 Herpes dermatitis Diseases 0.000 claims description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims description 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 2
- 206010023347 Keratoacanthoma Diseases 0.000 claims description 2
- 201000008197 Laryngitis Diseases 0.000 claims description 2
- 206010024238 Leptospirosis Diseases 0.000 claims description 2
- 208000004852 Lung Injury Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims description 2
- 201000009906 Meningitis Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 208000003926 Myelitis Diseases 0.000 claims description 2
- 208000009525 Myocarditis Diseases 0.000 claims description 2
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims description 2
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims description 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
- 206010031252 Osteomyelitis Diseases 0.000 claims description 2
- 208000005141 Otitis Diseases 0.000 claims description 2
- 208000027868 Paget disease Diseases 0.000 claims description 2
- 206010034038 Parotitis Diseases 0.000 claims description 2
- 206010034277 Pemphigoid Diseases 0.000 claims description 2
- 201000011152 Pemphigus Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000007452 Plasmacytoma Diseases 0.000 claims description 2
- 206010065159 Polychondritis Diseases 0.000 claims description 2
- 206010036105 Polyneuropathy Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 206010036774 Proctitis Diseases 0.000 claims description 2
- 206010036790 Productive cough Diseases 0.000 claims description 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims description 2
- 208000017442 Retinal disease Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims description 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 206010047642 Vitiligo Diseases 0.000 claims description 2
- 206010069351 acute lung injury Diseases 0.000 claims description 2
- 208000009956 adenocarcinoma Diseases 0.000 claims description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims description 2
- 208000004631 alopecia areata Diseases 0.000 claims description 2
- 230000036783 anaphylactic response Effects 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 2
- 208000010217 blepharitis Diseases 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims description 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims description 2
- 230000001925 catabolic effect Effects 0.000 claims description 2
- 206010008323 cervicitis Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000003167 cholangitis Diseases 0.000 claims description 2
- 201000001352 cholecystitis Diseases 0.000 claims description 2
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims description 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 206010009887 colitis Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000003146 cystitis Diseases 0.000 claims description 2
- 208000007784 diverticulitis Diseases 0.000 claims description 2
- 208000019258 ear infection Diseases 0.000 claims description 2
- 210000003981 ectoderm Anatomy 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 206010014665 endocarditis Diseases 0.000 claims description 2
- 230000002124 endocrine Effects 0.000 claims description 2
- 208000010227 enterocolitis Diseases 0.000 claims description 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims description 2
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims description 2
- 208000030941 fetal growth restriction Diseases 0.000 claims description 2
- 230000003325 follicular Effects 0.000 claims description 2
- 208000005017 glioblastoma Diseases 0.000 claims description 2
- 231100000852 glomerular disease Toxicity 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 208000014951 hematologic disease Diseases 0.000 claims description 2
- 208000007475 hemolytic anemia Diseases 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims description 2
- 210000004276 hyalin Anatomy 0.000 claims description 2
- 206010020718 hyperplasia Diseases 0.000 claims description 2
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims description 2
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims description 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims description 2
- 201000008319 inclusion body myositis Diseases 0.000 claims description 2
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 claims description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 2
- 206010023332 keratitis Diseases 0.000 claims description 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 201000011486 lichen planus Diseases 0.000 claims description 2
- 231100000515 lung injury Toxicity 0.000 claims description 2
- 208000027202 mammary Paget disease Diseases 0.000 claims description 2
- 208000004396 mastitis Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 208000009928 nephrosis Diseases 0.000 claims description 2
- 231100001027 nephrosis Toxicity 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims description 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 2
- 208000008494 pericarditis Diseases 0.000 claims description 2
- 230000000737 periodic effect Effects 0.000 claims description 2
- 201000001245 periodontitis Diseases 0.000 claims description 2
- 206010034674 peritonitis Diseases 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 208000008423 pleurisy Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 230000007824 polyneuropathy Effects 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 2
- 206010039083 rhinitis Diseases 0.000 claims description 2
- 201000000306 sarcoidosis Diseases 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 206010062113 splenic marginal zone lymphoma Diseases 0.000 claims description 2
- 210000003802 sputum Anatomy 0.000 claims description 2
- 208000024794 sputum Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 208000003265 stomatitis Diseases 0.000 claims description 2
- 201000004595 synovitis Diseases 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 210000001550 testis Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 206010043778 thyroiditis Diseases 0.000 claims description 2
- 206010044008 tonsillitis Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 208000018464 vernal keratoconjunctivitis Diseases 0.000 claims description 2
- 208000002003 vulvitis Diseases 0.000 claims description 2
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 1
- 206010048768 Dermatosis Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 230000003416 augmentation Effects 0.000 claims 1
- 125000002720 diazolyl group Chemical group 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 210000000918 epididymis Anatomy 0.000 claims 1
- 201000010063 epididymitis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000003800 pharynx Anatomy 0.000 claims 1
- 201000004537 pyelitis Diseases 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 153
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 116
- 238000006243 chemical reaction Methods 0.000 description 96
- 238000002360 preparation method Methods 0.000 description 84
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 77
- 239000000203 mixture Substances 0.000 description 64
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 63
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 62
- 239000000243 solution Substances 0.000 description 62
- 239000000543 intermediate Substances 0.000 description 60
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 55
- 235000019439 ethyl acetate Nutrition 0.000 description 55
- 239000000047 product Substances 0.000 description 53
- 238000004128 high performance liquid chromatography Methods 0.000 description 52
- 239000011541 reaction mixture Substances 0.000 description 50
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 42
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 39
- 239000011734 sodium Substances 0.000 description 30
- 229940079593 drug Drugs 0.000 description 28
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 26
- 239000002904 solvent Substances 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 21
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 20
- 230000002829 reductive effect Effects 0.000 description 20
- 239000000376 reactant Substances 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 19
- 108010072621 Interleukin-1 Receptor-Associated Kinases Proteins 0.000 description 18
- 102000006940 Interleukin-1 Receptor-Associated Kinases Human genes 0.000 description 18
- 125000001424 substituent group Chemical group 0.000 description 18
- 230000001225 therapeutic effect Effects 0.000 description 18
- 238000009472 formulation Methods 0.000 description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 16
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 15
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 15
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 14
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 238000004440 column chromatography Methods 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000003112 inhibitor Substances 0.000 description 13
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 13
- 238000010898 silica gel chromatography Methods 0.000 description 13
- LKLDHJQEIFNERC-UHFFFAOYSA-N 2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound C1=NC(C)=CC(C=2OC=C(N=2)C(O)=O)=C1 LKLDHJQEIFNERC-UHFFFAOYSA-N 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000460 chlorine Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- KEJFADGISRFLFO-UHFFFAOYSA-N 1H-indazol-6-amine Chemical compound NC1=CC=C2C=NNC2=C1 KEJFADGISRFLFO-UHFFFAOYSA-N 0.000 description 11
- 238000010521 absorption reaction Methods 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000003826 tablet Substances 0.000 description 10
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 125000004429 atom Chemical group 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 102000020233 phosphotransferase Human genes 0.000 description 9
- 125000003545 alkoxy group Chemical group 0.000 description 8
- 239000003054 catalyst Substances 0.000 description 8
- CSJLBAMHHLJAAS-UHFFFAOYSA-N diethylaminosulfur trifluoride Chemical compound CCN(CC)S(F)(F)F CSJLBAMHHLJAAS-UHFFFAOYSA-N 0.000 description 8
- 125000005842 heteroatom Chemical group 0.000 description 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 8
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
- 229910000029 sodium carbonate Inorganic materials 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 7
- 235000019270 ammonium chloride Nutrition 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000003480 eluent Substances 0.000 description 7
- 239000007903 gelatin capsule Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- JBCFJMYPJJWIRG-UHFFFAOYSA-N 1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC=N1 JBCFJMYPJJWIRG-UHFFFAOYSA-N 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 6
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 6
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000011149 active material Substances 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- 238000004821 distillation Methods 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000005457 ice water Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000001819 mass spectrum Methods 0.000 description 6
- 235000019198 oils Nutrition 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 229920000642 polymer Polymers 0.000 description 6
- 235000011056 potassium acetate Nutrition 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 6
- 239000007921 spray Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 5
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 5
- OAFFSZXCGQHGOX-AWEZNQCLSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C OAFFSZXCGQHGOX-AWEZNQCLSA-N 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229940043355 kinase inhibitor Drugs 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000006072 paste Substances 0.000 description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 4
- 239000007821 HATU Substances 0.000 description 4
- 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 4
- 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 108091054455 MAP kinase family Proteins 0.000 description 4
- 102000043136 MAP kinase family Human genes 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 102000002689 Toll-like receptor Human genes 0.000 description 4
- 108020000411 Toll-like receptor Proteins 0.000 description 4
- 229920001615 Tragacanth Polymers 0.000 description 4
- MMJPJAKZQDNXGR-LBPRGKRZSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C1=CC=CC(=N1)C(=O)O Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C1=CC=CC(=N1)C(=O)O MMJPJAKZQDNXGR-LBPRGKRZSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- 239000004006 olive oil Substances 0.000 description 4
- 235000008390 olive oil Nutrition 0.000 description 4
- 150000002894 organic compounds Chemical class 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 235000010487 tragacanth Nutrition 0.000 description 4
- 239000000196 tragacanth Substances 0.000 description 4
- 229940116362 tragacanth Drugs 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 239000000080 wetting agent Substances 0.000 description 4
- NDSDGUULXHNXGA-RPDRRWSUSA-N (1r,2s)-1-[(6r)-2,4-diamino-5,6,7,8-tetrahydropteridin-6-yl]propane-1,2-diol Chemical compound NC1=NC(N)=C2N[C@@H]([C@@H](O)[C@@H](O)C)CNC2=N1 NDSDGUULXHNXGA-RPDRRWSUSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- UHZSHWZWXFOHND-UHFFFAOYSA-N 2-(1h-pyrrolo[2,3-b]pyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=COC(C=2C=3C=CNC=3N=CC=2)=N1 UHZSHWZWXFOHND-UHFFFAOYSA-N 0.000 description 3
- AHGDHKGRZYEULD-UHFFFAOYSA-N 2-(2-amino-3-fluoropyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound NC1=NC=CC(=C1F)C=1OC=C(N=1)C(=O)O AHGDHKGRZYEULD-UHFFFAOYSA-N 0.000 description 3
- UQTAUHHGOGFRMC-UHFFFAOYSA-N 2-(2-aminopyridin-3-yl)-1,3-oxazole-4-carboxylic acid Chemical compound NC1=NC=CC=C1C=1OC=C(N=1)C(=O)O UQTAUHHGOGFRMC-UHFFFAOYSA-N 0.000 description 3
- AENSHIAQYPGSGO-UHFFFAOYSA-N 2-(2-cyclopropylpyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound C1(CC1)C1=NC=CC(=C1)C=1OC=C(N=1)C(=O)O AENSHIAQYPGSGO-UHFFFAOYSA-N 0.000 description 3
- PVFMGKNVTXKRCC-QMMMGPOBSA-N 2-[(3S)-3-[(2-methylpropan-2-yl)oxycarbonylamino]pyrrolidin-1-yl]-1,3-oxazole-4-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N[C@@H]1CN(CC1)C=1OC=C(N1)C(=O)O PVFMGKNVTXKRCC-QMMMGPOBSA-N 0.000 description 3
- IRALORQBDQILNQ-UHFFFAOYSA-N 4-methyl-2-(2-methylpyridin-4-yl)-1,3-oxazole-5-carboxylic acid Chemical compound CC=1N=C(OC=1C(=O)O)C1=CC(=NC=C1)C IRALORQBDQILNQ-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- 239000005541 ACE inhibitor Substances 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010069754 Acquired gene mutation Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- BXDZOYLPNAIDOC-UHFFFAOYSA-N N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]-1-[2-[2-[2-[2-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-4-yl]amino]ethoxy]ethoxy]ethoxy]ethylamino]-2-oxoethyl]piperidine-4-carboxamide Chemical compound CC(C)(C)c1cnc(CSc2cnc(NC(=O)C3CCN(CC(=O)NCCOCCOCCOCCNc4cccc5C(=O)N(C6CCC(=O)NC6=O)C(=O)c45)CC3)s2)o1 BXDZOYLPNAIDOC-UHFFFAOYSA-N 0.000 description 3
- 102000003945 NF-kappa B Human genes 0.000 description 3
- 108010057466 NF-kappa B Proteins 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000006044 T cell activation Effects 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 235000010419 agar Nutrition 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 235000012216 bentonite Nutrition 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940030606 diuretics Drugs 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
- 230000004770 neurodegeneration Effects 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 125000006413 ring segment Chemical group 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 230000037439 somatic mutation Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- JHHZLHWJQPUNKB-BYPYZUCNSA-N (3s)-pyrrolidin-3-ol Chemical compound O[C@H]1CCNC1 JHHZLHWJQPUNKB-BYPYZUCNSA-N 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- KRPZOMRZEOAMED-UHFFFAOYSA-N 1-(5-fluoroindazol-1-yl)ethanone Chemical compound FC1=CC=C2N(C(=O)C)N=CC2=C1 KRPZOMRZEOAMED-UHFFFAOYSA-N 0.000 description 2
- SVKDCDOKGDZDJF-UHFFFAOYSA-N 1-methyl-5-piperidin-1-ylindazol-6-amine Chemical compound CN1N=CC2=C1C=C(N)C(=C2)N1CCCCC1 SVKDCDOKGDZDJF-UHFFFAOYSA-N 0.000 description 2
- UFLSDPVLVHPCGQ-UHFFFAOYSA-N 1-methyl-6-nitro-5-piperidin-1-ylindazole Chemical compound CN1N=CC2=C1C=C(C(=C2)N1CCCCC1)[N+]([O-])=O UFLSDPVLVHPCGQ-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 2
- MVLPMUBAIMFXQE-UHFFFAOYSA-N 2-(2-acetamidopyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound C(C)(=O)NC1=NC=CC(=C1)C=1OC=C(N1)C(=O)O MVLPMUBAIMFXQE-UHFFFAOYSA-N 0.000 description 2
- CAWXWHKFZYVSBR-UHFFFAOYSA-N 2-(2-aminopyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound NC1=NC=CC(=C1)C=1OC=C(N1)C(=O)O CAWXWHKFZYVSBR-UHFFFAOYSA-N 0.000 description 2
- FSXZCNBEJUPCTJ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)-1,3-oxazole-4-carboxylic acid Chemical compound C1CN(C)CCN1C1=NC(C(O)=O)=CO1 FSXZCNBEJUPCTJ-UHFFFAOYSA-N 0.000 description 2
- SNYSSYRZZOVXHF-UHFFFAOYSA-N 2-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]-1,3-oxazole-4-carboxylic acid Chemical compound C(C)(C)(C)OC(=O)N1CCN(CC1)C=1OC=C(N=1)C(=O)O SNYSSYRZZOVXHF-UHFFFAOYSA-N 0.000 description 2
- NIDNULZJTYZLJZ-UHFFFAOYSA-N 2-methyl-6-nitro-5-piperidin-1-ylindazole Chemical compound CN1N=C2C=C(C(=CC2=C1)N1CCCCC1)[N+](=O)[O-] NIDNULZJTYZLJZ-UHFFFAOYSA-N 0.000 description 2
- KMHLGVTVACLEJE-UHFFFAOYSA-N 4-fluoro-2-methylaniline Chemical compound CC1=CC(F)=CC=C1N KMHLGVTVACLEJE-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- USAKMILGFGKFGU-UHFFFAOYSA-N 5-(3-fluoropiperidin-1-yl)-1-methylindazol-6-amine Chemical compound FC1CN(CCC1)C=1C=C2C=NN(C2=CC=1N)C USAKMILGFGKFGU-UHFFFAOYSA-N 0.000 description 2
- CMBCEKXQUBSBEE-UHFFFAOYSA-N 5-(3-fluoropiperidin-1-yl)-2-methylindazol-6-amine Chemical compound FC1CN(CCC1)C1=CC2=CN(N=C2C=C1N)C CMBCEKXQUBSBEE-UHFFFAOYSA-N 0.000 description 2
- DQSAFHLOZZZDDO-UHFFFAOYSA-N 5-(3-fluoropiperidin-1-yl)-6-nitro-1H-indazole Chemical compound FC1CN(CCC1)C=1C=C2C=NNC2=CC=1[N+](=O)[O-] DQSAFHLOZZZDDO-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- BSABHYCZUVLTJP-UHFFFAOYSA-N BrC1=NNC2=CC(=C(C=C12)N1CCC(CC1)CO[Si](C)(C)C(C)(C)C)[N+](=O)[O-] Chemical compound BrC1=NNC2=CC(=C(C=C12)N1CCC(CC1)CO[Si](C)(C)C(C)(C)C)[N+](=O)[O-] BSABHYCZUVLTJP-UHFFFAOYSA-N 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- GUFDRAMXFWMSOH-JTQLQIEISA-N C(C)(C)(C)[Si](O[C@@H]1CN(CC1)C=1OC=C(N1)C(=O)O)(C)C Chemical compound C(C)(C)(C)[Si](O[C@@H]1CN(CC1)C=1OC=C(N1)C(=O)O)(C)C GUFDRAMXFWMSOH-JTQLQIEISA-N 0.000 description 2
- 0 C*C(C(*)=C[C@]1C(C*)NNC(*)C1)=C Chemical compound C*C(C(*)=C[C@]1C(C*)NNC(*)C1)=C 0.000 description 2
- QHEKCNSNESDKNT-UHFFFAOYSA-N CN1N=C(C)C2=C1C=C(N)C(=C2)N1CCC(CO[Si](C)(C)C(C)(C)C)CC1 Chemical compound CN1N=C(C)C2=C1C=C(N)C(=C2)N1CCC(CO[Si](C)(C)C(C)(C)C)CC1 QHEKCNSNESDKNT-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010052167 Dihydroorotate Dehydrogenase Proteins 0.000 description 2
- 102100032823 Dihydroorotate dehydrogenase (quinone), mitochondrial Human genes 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- BZQWIJMXQPQBLZ-UHFFFAOYSA-N N-[5-(4-hydroxypiperidin-1-yl)-2-methylindazol-6-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Chemical compound Cl.Cn1cc2cc(N3CCC(O)CC3)c(NC(=O)c3cnn4cccnc34)cc2n1 BZQWIJMXQPQBLZ-UHFFFAOYSA-N 0.000 description 2
- 150000001204 N-oxides Chemical class 0.000 description 2
- 208000012902 Nervous system disease Diseases 0.000 description 2
- 208000025966 Neurological disease Diseases 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- OPNXRVIAPJZKBR-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OC1CCN(CC1)C1=CC2=CN(N=C2C=C1N)C Chemical compound [Si](C)(C)(C(C)(C)C)OC1CCN(CC1)C1=CC2=CN(N=C2C=C1N)C OPNXRVIAPJZKBR-UHFFFAOYSA-N 0.000 description 2
- KQYDNROVGCLWPN-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OC1CCN(CC1)C1=CC2=CN(N=C2C=C1[N+](=O)[O-])C Chemical compound [Si](C)(C)(C(C)(C)C)OC1CCN(CC1)C1=CC2=CN(N=C2C=C1[N+](=O)[O-])C KQYDNROVGCLWPN-UHFFFAOYSA-N 0.000 description 2
- VGCRNNSPYYIUPL-INIZCTEOSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C1CC1 Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C1CC1 VGCRNNSPYYIUPL-INIZCTEOSA-N 0.000 description 2
- DIGAPYIAEOCGOT-ZDUSSCGKSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NNC2=CC=1[N+](=O)[O-] Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NNC2=CC=1[N+](=O)[O-] DIGAPYIAEOCGOT-ZDUSSCGKSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 239000012876 carrier material Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 229960003677 chloroquine Drugs 0.000 description 2
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 description 2
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- WLVKDFJTYKELLQ-UHFFFAOYSA-N cyclopropylboronic acid Chemical compound OB(O)C1CC1 WLVKDFJTYKELLQ-UHFFFAOYSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 239000002988 disease modifying antirheumatic drug Substances 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- SYWQOPRAPDMWMC-UHFFFAOYSA-N ethyl 2-chloro-1,3-oxazole-4-carboxylate Chemical compound CCOC(=O)C1=COC(Cl)=N1 SYWQOPRAPDMWMC-UHFFFAOYSA-N 0.000 description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
- 229940093471 ethyl oleate Drugs 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 208000018706 hematopoietic system disease Diseases 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 229960000905 indomethacin Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 229940117681 interleukin-12 Drugs 0.000 description 2
- 229940124829 interleukin-23 Drugs 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229960002373 loxoprofen Drugs 0.000 description 2
- BAZQYVYVKYOAGO-UHFFFAOYSA-M loxoprofen sodium hydrate Chemical compound O.O.[Na+].C1=CC(C(C([O-])=O)C)=CC=C1CC1C(=O)CCC1 BAZQYVYVKYOAGO-UHFFFAOYSA-M 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000002895 organic esters Chemical class 0.000 description 2
- 125000004287 oxazol-2-yl group Chemical group [H]C1=C([H])N=C(*)O1 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- 229960001639 penicillamine Drugs 0.000 description 2
- CPJSUEIXXCENMM-UHFFFAOYSA-N phenacetin Chemical compound CCOC1=CC=C(NC(C)=O)C=C1 CPJSUEIXXCENMM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 125000003367 polycyclic group Chemical group 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- HNYVPKNVKSTVJO-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine-3-carboxylic acid Chemical compound C1=CC=NC2=C(C(=O)O)C=NN21 HNYVPKNVKSTVJO-UHFFFAOYSA-N 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229960001860 salicylate Drugs 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000007909 solid dosage form Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000008174 sterile solution Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000004797 therapeutic response Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 210000003932 urinary bladder Anatomy 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WEEYASWRWODDTJ-ZDUSSCGKSA-N (2s)-2-[[4-[(2,4-diaminopteridin-6-yl)methyl]-2,3-dihydro-1,4-benzothiazine-7-carbonyl]amino]hexanedioic acid Chemical compound C1CSC2=CC(C(=O)N[C@@H](CCCC(O)=O)C(O)=O)=CC=C2N1CC1=NC2=C(N)N=C(N)N=C2N=C1 WEEYASWRWODDTJ-ZDUSSCGKSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- IOLNNBMPQKWUDD-QMMMGPOBSA-N (3S)-1-(6-nitro-1H-indazol-5-yl)pyrrolidin-3-ol Chemical compound [N+](=O)([O-])C1=C(C=C2C=NNC2=C1)N1C[C@H](CC1)O IOLNNBMPQKWUDD-QMMMGPOBSA-N 0.000 description 1
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- LKJPYSCBVHEWIU-KRWDZBQOSA-N (R)-bicalutamide Chemical compound C([C@@](O)(C)C(=O)NC=1C=C(C(C#N)=CC=1)C(F)(F)F)S(=O)(=O)C1=CC=C(F)C=C1 LKJPYSCBVHEWIU-KRWDZBQOSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IBOXSBZTFHLWAN-UHFFFAOYSA-N 1,3-oxazole-4-carboxamide hydrochloride Chemical compound Cl.NC(=O)c1cocn1 IBOXSBZTFHLWAN-UHFFFAOYSA-N 0.000 description 1
- GWVCSBROQGVPHR-UHFFFAOYSA-N 1-(4-amino-5-methyl-2-nitrophenyl)piperidin-3-ol Chemical compound CC1=CC(N2CCCC(O)C2)=C(C=C1N)[N+]([O-])=O GWVCSBROQGVPHR-UHFFFAOYSA-N 0.000 description 1
- HGLJGFMGEOLFQL-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(B3OC(C)(C)C(C)(C)O3)=C2C=C1 HGLJGFMGEOLFQL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- XUGIDIROGIHNMI-UHFFFAOYSA-N 1-[5-(3-hydroxypiperidin-1-yl)-6-nitroindazol-1-yl]ethanone Chemical compound CC(=O)N1N=CC2=C1C=C(C(=C2)N1CCCC(O)C1)[N+]([O-])=O XUGIDIROGIHNMI-UHFFFAOYSA-N 0.000 description 1
- VSNHCAURESNICA-NJFSPNSNSA-N 1-oxidanylurea Chemical compound N[14C](=O)NO VSNHCAURESNICA-NJFSPNSNSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- ABEXEQSGABRUHS-UHFFFAOYSA-N 16-methylheptadecyl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C ABEXEQSGABRUHS-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- UUYWHZBLUYIDST-UHFFFAOYSA-N 1h-benzimidazole;1h-indazole Chemical compound C1=CC=C2NC=NC2=C1.C1=CC=C2C=NNC2=C1 UUYWHZBLUYIDST-UHFFFAOYSA-N 0.000 description 1
- DPXSYNFIIJWVBQ-UHFFFAOYSA-N 2-(2,6-dimethylpyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound CC1=NC(=CC(=C1)C=1OC=C(N1)C(=O)O)C DPXSYNFIIJWVBQ-UHFFFAOYSA-N 0.000 description 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 description 1
- FRPQEEDWULPKBJ-UHFFFAOYSA-N 2-(2-ethylpyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound C(C)C1=NC=CC(=C1)C=1OC=C(N=1)C(=O)O FRPQEEDWULPKBJ-UHFFFAOYSA-N 0.000 description 1
- OBUTVQUSQRHRKT-UHFFFAOYSA-N 2-(2-methylpyridin-4-yl)-1,3-oxazole-5-carboxylic acid Chemical compound CC1=NC=CC(=C1)C=1OC(=CN=1)C(=O)O OBUTVQUSQRHRKT-UHFFFAOYSA-N 0.000 description 1
- BCIGEDPRARFVTC-UHFFFAOYSA-N 2-(2-methylpyrimidin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound CC1=NC=CC(=N1)C=1OC=C(N=1)C(=O)O BCIGEDPRARFVTC-UHFFFAOYSA-N 0.000 description 1
- VEEYJJQXIMCWKI-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]-3,6-dihydro-2h-pyridin-4-yl]-1,3-oxazole-4-carboxylic acid Chemical compound C1N(C(=O)OC(C)(C)C)CCC(C=2OC=C(N=2)C(O)=O)=C1 VEEYJJQXIMCWKI-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- MNHUVWMNRKYGGI-UHFFFAOYSA-N 2-bromo-4-chloro-3-fluoropyridine Chemical compound FC1=C(Cl)C=CN=C1Br MNHUVWMNRKYGGI-UHFFFAOYSA-N 0.000 description 1
- SSXYKBHZZRYLLY-UHFFFAOYSA-N 2-chloro-1,3-oxazole Chemical compound ClC1=NC=CO1 SSXYKBHZZRYLLY-UHFFFAOYSA-N 0.000 description 1
- QFUFLFJZHFCDLM-UHFFFAOYSA-N 2-cyclopropylpyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C2CC2)=C1 QFUFLFJZHFCDLM-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- NLLGHSUQXFKJOL-UHFFFAOYSA-N 2-methyl-5-piperidin-1-ylindazol-6-amine Chemical compound CN1N=C2C=C(C(=CC2=C1)N1CCCCC1)N NLLGHSUQXFKJOL-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
- GTZNKPJWYCAHNU-UHFFFAOYSA-N 3-bromo-6-nitro-2H-indazol-5-ol Chemical compound BrC1=NNC2=CC(=C(C=C12)O)[N+](=O)[O-] GTZNKPJWYCAHNU-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
- ACMIJDVJWLMBCX-PXAZEXFGSA-N 4-[(3ar,6ar)-2,3,3a,4,6,6a-hexahydro-1h-pyrrolo[2,3-c]pyrrol-5-yl]-6-fluoro-n-methyl-2-(2-methylpyrimidin-5-yl)oxy-9h-pyrimido[4,5-b]indol-8-amine Chemical compound CNC1=CC(F)=CC(C2=C(N3C[C@@H]4NCC[C@@H]4C3)N=3)=C1NC2=NC=3OC1=CN=C(C)N=C1 ACMIJDVJWLMBCX-PXAZEXFGSA-N 0.000 description 1
- GDTQLZHHDRRBEB-UHFFFAOYSA-N 4-[5-(cyclopropylcarbamoyl)-2-methylanilino]-5-methyl-n-propylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide Chemical compound C12=C(C)C(C(=O)NCCC)=CN2N=CN=C1NC(C(=CC=1)C)=CC=1C(=O)NC1CC1 GDTQLZHHDRRBEB-UHFFFAOYSA-N 0.000 description 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 description 1
- RXOUGGMZMDZDCE-UHFFFAOYSA-N 4-chloro-1-(4-methylphenyl)sulfonylpyrrolo[2,3-b]pyridine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1C2=NC=CC(Cl)=C2C=C1 RXOUGGMZMDZDCE-UHFFFAOYSA-N 0.000 description 1
- HNTZVGMWXCFCTA-UHFFFAOYSA-N 4-chloro-1h-pyrrolo[2,3-b]pyridine Chemical compound ClC1=CC=NC2=C1C=CN2 HNTZVGMWXCFCTA-UHFFFAOYSA-N 0.000 description 1
- LHIUCVZCVMTRNG-UHFFFAOYSA-N 4-fluoro-2-methyl-5-nitroaniline Chemical compound CC1=CC(F)=C([N+]([O-])=O)C=C1N LHIUCVZCVMTRNG-UHFFFAOYSA-N 0.000 description 1
- FBEMJIHUIXBFDB-UHFFFAOYSA-N 5-(3-fluoropiperidin-1-yl)-1-methyl-6-nitroindazole Chemical compound FC1CN(CCC1)C=1C=C2C=NN(C2=CC=1[N+](=O)[O-])C FBEMJIHUIXBFDB-UHFFFAOYSA-N 0.000 description 1
- WXLGHNBTOHOZBG-UHFFFAOYSA-N 5-(4-fluoropiperidin-1-yl)-1-methylindazol-6-amine Chemical compound FC1CCN(CC1)C=1C=C2C=NN(C2=CC=1N)C WXLGHNBTOHOZBG-UHFFFAOYSA-N 0.000 description 1
- LIWIWTHSKJBYDW-UHFFFAOYSA-N 5-fluoro-1h-indazole Chemical compound FC1=CC=C2NN=CC2=C1 LIWIWTHSKJBYDW-UHFFFAOYSA-N 0.000 description 1
- WFZSVCPNBMDDAC-UHFFFAOYSA-N 5-methyl-2-(2-methylpyridin-4-yl)-1,3-oxazole-4-carboxylic acid Chemical compound CC1=C(N=C(O1)C1=CC(=NC=C1)C)C(=O)O WFZSVCPNBMDDAC-UHFFFAOYSA-N 0.000 description 1
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 description 1
- XDBHURGONHZNJF-UHFFFAOYSA-N 6-[2-(3,4-diethoxyphenyl)-1,3-thiazol-4-yl]pyridine-2-carboxylic acid Chemical compound C1=C(OCC)C(OCC)=CC=C1C1=NC(C=2N=C(C=CC=2)C(O)=O)=CS1 XDBHURGONHZNJF-UHFFFAOYSA-N 0.000 description 1
- XURXQNUIGWHWHU-UHFFFAOYSA-N 6-bromopyridine-2-carboxylic acid Chemical compound OC(=O)C1=CC=CC(Br)=N1 XURXQNUIGWHWHU-UHFFFAOYSA-N 0.000 description 1
- BKYKPTRYDKTTJY-UHFFFAOYSA-N 6-chloro-3-(cyclopentylmethyl)-1,1-dioxo-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1CCCC1 BKYKPTRYDKTTJY-UHFFFAOYSA-N 0.000 description 1
- ZTESLDUVNLLWPD-UHFFFAOYSA-N 6-nitro-5-piperidin-1-yl-1H-indazole Chemical compound [N+](=O)([O-])C1=C(C=C2C=NNC2=C1)N1CCCCC1 ZTESLDUVNLLWPD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 1
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 102100022718 Atypical chemokine receptor 2 Human genes 0.000 description 1
- 239000005485 Azilsartan Substances 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- MNIPYSSQXLZQLJ-UHFFFAOYSA-N Biofenac Chemical compound OC(=O)COC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl MNIPYSSQXLZQLJ-UHFFFAOYSA-N 0.000 description 1
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical compound N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 239000002080 C09CA02 - Eprosartan Substances 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 description 1
- 239000002053 C09CA06 - Candesartan Substances 0.000 description 1
- 239000003861 C09CA09 - Azilsartan medoxomil Substances 0.000 description 1
- XVYLRVWEFXASHD-UHFFFAOYSA-N COC(=O)c1ccnc(c1)C1CC1 Chemical compound COC(=O)c1ccnc(c1)C1CC1 XVYLRVWEFXASHD-UHFFFAOYSA-N 0.000 description 1
- 229940124803 CXCR2 antagonist Drugs 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- QCTQAYLHEPCSTB-FQEVSTJZSA-N C[n](c1c2)ncc1cc(N(CC1)C[C@H]1O)c2NC(C1=CCCCC(c2cc(C3CC3)ncc2)=N1)=O Chemical compound C[n](c1c2)ncc1cc(N(CC1)C[C@H]1O)c2NC(C1=CCCCC(c2cc(C3CC3)ncc2)=N1)=O QCTQAYLHEPCSTB-FQEVSTJZSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 229940123150 Chelating agent Drugs 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- ITRJWOMZKQRYTA-RFZYENFJSA-N Cortisone acetate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)COC(=O)C)(O)[C@@]1(C)CC2=O ITRJWOMZKQRYTA-RFZYENFJSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102100025621 Cytochrome b-245 heavy chain Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- VVNCNSJFMMFHPL-VKHMYHEASA-N D-penicillamine Chemical compound CC(C)(S)[C@@H](N)C(O)=O VVNCNSJFMMFHPL-VKHMYHEASA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 206010015218 Erythema multiforme Diseases 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108010008165 Etanercept Proteins 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 239000008961 HMPL-004 Substances 0.000 description 1
- 206010066476 Haematological malignancy Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000678892 Homo sapiens Atypical chemokine receptor 2 Proteins 0.000 description 1
- 101000716070 Homo sapiens C-C chemokine receptor type 9 Proteins 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 229940124790 IL-6 inhibitor Drugs 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- ANMATWQYLIFGOK-UHFFFAOYSA-N Iguratimod Chemical compound CS(=O)(=O)NC1=CC=2OC=C(NC=O)C(=O)C=2C=C1OC1=CC=CC=C1 ANMATWQYLIFGOK-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 229940123658 Interleukin 2 receptor antagonist Drugs 0.000 description 1
- 229940124103 Interleukin 6 antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- 102100023530 Interleukin-1 receptor-associated kinase 3 Human genes 0.000 description 1
- 101710199012 Interleukin-1 receptor-associated kinase 3 Proteins 0.000 description 1
- 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
- 101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 102000004557 Interleukin-18 Receptors Human genes 0.000 description 1
- 108010017537 Interleukin-18 Receptors Proteins 0.000 description 1
- 102000013264 Interleukin-23 Human genes 0.000 description 1
- 108010065637 Interleukin-23 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000764238 Isis Species 0.000 description 1
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-M L-tartrate(1-) Chemical compound OC(=O)[C@H](O)[C@@H](O)C([O-])=O FEWJPZIEWOKRBE-JCYAYHJZSA-M 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 description 1
- 102000005482 Lipopolysaccharide Receptors Human genes 0.000 description 1
- 108010031801 Lipopolysaccharide Receptors Proteins 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229940123313 MCP-1 antagonist Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- SBDNJUWAMKYJOX-UHFFFAOYSA-N Meclofenamic Acid Chemical compound CC1=CC=C(Cl)C(NC=2C(=CC=CC=2)C(O)=O)=C1Cl SBDNJUWAMKYJOX-UHFFFAOYSA-N 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- ZMIAMRGYNQTQEI-ZOWNYOTGSA-N N-[5-[(3S)-3-hydroxypyrrolidin-1-yl]-1-methylindazol-6-yl]pyrazolo[1,5-a]pyrimidine-3-carboxamide hydrochloride Chemical compound Cl.Cn1ncc2cc(N3CC[C@H](O)C3)c(NC(=O)c3cnn4cccnc34)cc12 ZMIAMRGYNQTQEI-ZOWNYOTGSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- ZMFKXTFTNSLTGQ-UHFFFAOYSA-N OP(=O)C#N Chemical compound OP(=O)C#N ZMFKXTFTNSLTGQ-UHFFFAOYSA-N 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 239000005480 Olmesartan Substances 0.000 description 1
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229940049937 Pgp inhibitor Drugs 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 108050003243 Prostaglandin G/H synthase 1 Proteins 0.000 description 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- UKNGDQSYPNBJAO-UHFFFAOYSA-N Tiaramide hydrochloride Chemical compound Cl.C1CN(CCO)CCN1C(=O)CN1C(=O)SC2=CC=C(Cl)C=C21 UKNGDQSYPNBJAO-UHFFFAOYSA-N 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- MUXFZBHBYYYLTH-UHFFFAOYSA-N Zaltoprofen Chemical compound O=C1CC2=CC(C(C(O)=O)C)=CC=C2SC2=CC=CC=C21 MUXFZBHBYYYLTH-UHFFFAOYSA-N 0.000 description 1
- QKLDCEYHDKPVDK-PRIYMHJNSA-N [(8r,9s,13s,14s,16r,17r)-16-hydroxy-13-methyl-3-propanoyloxy-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1CC2=CC(OC(=O)CC)=CC=C2[C@@H]2[C@@H]1[C@@H]1C[C@@H](O)[C@H](OC(=O)CC)[C@@]1(C)CC2 QKLDCEYHDKPVDK-PRIYMHJNSA-N 0.000 description 1
- IZHJMWGTCLQCOW-UHFFFAOYSA-N [1-(3-bromo-6-nitro-2H-indazol-5-yl)piperidin-4-yl]methanol Chemical compound BrC1=NNC2=CC(=C(C=C12)N1CCC(CC1)CO)[N+](=O)[O-] IZHJMWGTCLQCOW-UHFFFAOYSA-N 0.000 description 1
- HRDFTGSCBVFCCM-UHFFFAOYSA-N [Si](C)(C)(C(C)(C)C)OC1CN(CCC1)C1=CC2=CN(N=C2C=C1N)C Chemical compound [Si](C)(C)(C(C)(C)C)OC1CN(CCC1)C1=CC2=CN(N=C2C=C1N)C HRDFTGSCBVFCCM-UHFFFAOYSA-N 0.000 description 1
- AQODRHMHMBZJOB-AWEZNQCLSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C1=CC2=CN(N=C2C=C1[N+](=O)[O-])C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C1=CC2=CN(N=C2C=C1[N+](=O)[O-])C AQODRHMHMBZJOB-AWEZNQCLSA-N 0.000 description 1
- KJHILUPGPAMEPW-HNNXBMFYSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)CC Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)CC KJHILUPGPAMEPW-HNNXBMFYSA-N 0.000 description 1
- SCKJBLAXZVMYQA-INIZCTEOSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1[N+](=O)[O-])C1CC1 Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1[N+](=O)[O-])C1CC1 SCKJBLAXZVMYQA-INIZCTEOSA-N 0.000 description 1
- MSASXUATVIMTCY-HNNXBMFYSA-N [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1[N+](=O)[O-])CC Chemical compound [Si](C)(C)(C(C)(C)C)O[C@@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1[N+](=O)[O-])CC MSASXUATVIMTCY-HNNXBMFYSA-N 0.000 description 1
- OAFFSZXCGQHGOX-CQSZACIVSA-N [Si](C)(C)(C(C)(C)C)O[C@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C Chemical compound [Si](C)(C)(C(C)(C)C)O[C@H]1CN(CC1)C=1C=C2C=NN(C2=CC=1N)C OAFFSZXCGQHGOX-CQSZACIVSA-N 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 229960004420 aceclofenac Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 229960003459 allopurinol Drugs 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229960004909 aminosalicylic acid Drugs 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 229960001220 amsacrine Drugs 0.000 description 1
- XCPGHVQEEXUHNC-UHFFFAOYSA-N amsacrine Chemical compound COC1=CC(NS(C)(=O)=O)=CC=C1NC1=C(C=CC=C2)C2=NC2=CC=CC=C12 XCPGHVQEEXUHNC-UHFFFAOYSA-N 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 229960002932 anastrozole Drugs 0.000 description 1
- YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 239000003524 antilipemic agent Substances 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 239000003904 antiprotozoal agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000000164 antipsychotic agent Substances 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000003886 aromatase inhibitor Substances 0.000 description 1
- 229940046844 aromatase inhibitors Drugs 0.000 description 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229960005370 atorvastatin Drugs 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- KGSXMPPBFPAXLY-UHFFFAOYSA-N azilsartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NOC(=O)N1 KGSXMPPBFPAXLY-UHFFFAOYSA-N 0.000 description 1
- 229960002731 azilsartan Drugs 0.000 description 1
- 229960001211 azilsartan medoxomil Drugs 0.000 description 1
- QJFSABGVXDWMIW-UHFFFAOYSA-N azilsartan medoxomil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C=3NC(=O)ON=3)C(OCC)=NC2=CC=CC=1C(=O)OCC=1OC(=O)OC=1C QJFSABGVXDWMIW-UHFFFAOYSA-N 0.000 description 1
- 229960004168 balsalazide Drugs 0.000 description 1
- IPOKCKJONYRRHP-FMQUCBEESA-N balsalazide Chemical compound C1=CC(C(=O)NCCC(=O)O)=CC=C1\N=N\C1=CC=C(O)C(C(O)=O)=C1 IPOKCKJONYRRHP-FMQUCBEESA-N 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229960003515 bendroflumethiazide Drugs 0.000 description 1
- HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 1
- 229960002529 benzbromarone Drugs 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960000997 bicalutamide Drugs 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- 229960002874 briakinumab Drugs 0.000 description 1
- XNNQFQFUQLJSQT-UHFFFAOYSA-N bromo(trichloro)methane Chemical compound ClC(Cl)(Cl)Br XNNQFQFUQLJSQT-UHFFFAOYSA-N 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 229960000772 camostat Drugs 0.000 description 1
- FSEKIHNIDBATFG-UHFFFAOYSA-N camostat mesylate Chemical compound CS([O-])(=O)=O.C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C([NH+]=C(N)N)C=C1 FSEKIHNIDBATFG-UHFFFAOYSA-N 0.000 description 1
- 229960000932 candesartan Drugs 0.000 description 1
- 229960004349 candesartan cilexetil Drugs 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000004452 carbocyclyl group Chemical group 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 description 1
- 108010021331 carfilzomib Proteins 0.000 description 1
- 229960002438 carfilzomib Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 description 1
- 229960004195 carvedilol Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000016532 chronic granulomatous disease Diseases 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960003290 cortisone acetate Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000011262 co‐therapy Methods 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 229960003280 cupric chloride Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
- 229960003206 cyclopenthiazide Drugs 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000004663 dialkyl amino group Chemical group 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940120124 dichloroacetate Drugs 0.000 description 1
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 1
- 125000006003 dichloroethyl group Chemical group 0.000 description 1
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 1
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001193 diclofenac sodium Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000006001 difluoroethyl group Chemical group 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- 229960005156 digoxin Drugs 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 125000004982 dihaloalkyl group Chemical group 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 229960001089 dobutamine Drugs 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 229960004563 eprosartan Drugs 0.000 description 1
- OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 229960000403 etanercept Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SBNKFTQSBPKMBZ-UHFFFAOYSA-N ethenzamide Chemical compound CCOC1=CC=CC=C1C(N)=O SBNKFTQSBPKMBZ-UHFFFAOYSA-N 0.000 description 1
- LACXTUNIUGNJDW-UHFFFAOYSA-N ethyl 2-amino-4-methyl-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C=1OC(N)=NC=1C LACXTUNIUGNJDW-UHFFFAOYSA-N 0.000 description 1
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 1
- STXSAAHINIUMBV-UHFFFAOYSA-N ethyl 2-chloro-4-methyl-1,3-oxazole-5-carboxylate Chemical compound CCOC(=O)C=1OC(Cl)=NC=1C STXSAAHINIUMBV-UHFFFAOYSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229960005293 etodolac Drugs 0.000 description 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005167 everolimus Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 229940066493 expectorants Drugs 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 208000033699 familial Guillain-Barre syndrome Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 229960002011 fludrocortisone Drugs 0.000 description 1
- AAXVEMMRQDVLJB-BULBTXNYSA-N fludrocortisone Chemical compound O=C1CC[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 AAXVEMMRQDVLJB-BULBTXNYSA-N 0.000 description 1
- 229960004369 flufenamic acid Drugs 0.000 description 1
- LPEPZBJOKDYZAD-UHFFFAOYSA-N flufenamic acid Chemical compound OC(=O)C1=CC=CC=C1NC1=CC=CC(C(F)(F)F)=C1 LPEPZBJOKDYZAD-UHFFFAOYSA-N 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 229960001048 fluorometholone Drugs 0.000 description 1
- FAOZLTXFLGPHNG-KNAQIMQKSA-N fluorometholone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@]2(F)[C@@H](O)C[C@]2(C)[C@@](O)(C(C)=O)CC[C@H]21 FAOZLTXFLGPHNG-KNAQIMQKSA-N 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229960001751 fluoxymesterone Drugs 0.000 description 1
- YLRFCQOZQXIBAB-RBZZARIASA-N fluoxymesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C[C@@H]2O YLRFCQOZQXIBAB-RBZZARIASA-N 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical compound [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 229960003883 furosemide Drugs 0.000 description 1
- 229950000501 gabexate Drugs 0.000 description 1
- DNTNDFLIKUKKOC-UHFFFAOYSA-N gabexate methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=C(OC(=O)CCCCCN=C(N)[NH3+])C=C1 DNTNDFLIKUKKOC-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- 229940114119 gentisate Drugs 0.000 description 1
- 210000002816 gill Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000002748 glycoprotein P inhibitor Substances 0.000 description 1
- 229940015045 gold sodium thiomalate Drugs 0.000 description 1
- 229960001743 golimumab Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- IDINUJSAMVOPCM-UHFFFAOYSA-N gusperimus Chemical compound NCCCNCCCCNC(=O)C(O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- 125000005553 heteroaryloxy group Chemical group 0.000 description 1
- 229950001996 hexestrol Drugs 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 229950003909 iguratimod Drugs 0.000 description 1
- 238000005417 image-selected in vivo spectroscopy Methods 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- UTCSSFWDNNEEBH-UHFFFAOYSA-N imidazo[1,2-a]pyridine Chemical compound C1=CC=CC2=NC=CN21 UTCSSFWDNNEEBH-UHFFFAOYSA-N 0.000 description 1
- VTVRXITWWZGKHV-UHFFFAOYSA-N imidazo[1,2-b]pyridazine Chemical compound N1=CC=CC2=NC=CN21 VTVRXITWWZGKHV-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 229940125721 immunosuppressive agent Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- NDDAHWYSQHTHNT-UHFFFAOYSA-N indapamide Chemical compound CC1CC2=CC=CC=C2N1NC(=O)C1=CC=C(Cl)C(S(N)(=O)=O)=C1 NDDAHWYSQHTHNT-UHFFFAOYSA-N 0.000 description 1
- 229960004569 indapamide Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000012739 integrated shape imaging system Methods 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940076144 interleukin-10 Drugs 0.000 description 1
- 230000024949 interleukin-17 production Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229960002198 irbesartan Drugs 0.000 description 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-M isonicotinate Chemical compound [O-]C(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-M 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229960003406 levorphanol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- OXROWJKCGCOJDO-JLHYYAGUSA-N lornoxicam Chemical compound O=C1C=2SC(Cl)=CC=2S(=O)(=O)N(C)\C1=C(\O)NC1=CC=CC=N1 OXROWJKCGCOJDO-JLHYYAGUSA-N 0.000 description 1
- 229960002202 lornoxicam Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- 229960003803 meclofenamic acid Drugs 0.000 description 1
- 229960004616 medroxyprogesterone Drugs 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960001786 megestrol Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N megestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- AWIJRPNMLHPLNC-UHFFFAOYSA-N methanethioic s-acid Chemical compound SC=O AWIJRPNMLHPLNC-UHFFFAOYSA-N 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- ANSUDRATXSJBLY-VKHMYHEASA-N methyl (2s)-2-amino-3-hydroxypropanoate Chemical compound COC(=O)[C@@H](N)CO ANSUDRATXSJBLY-VKHMYHEASA-N 0.000 description 1
- ZXFCJCYGLCDKTM-UHFFFAOYSA-N methyl 2-(2-cyclopropylpyridin-4-yl)-4,5-dihydro-1,3-oxazole-4-carboxylate Chemical compound C1(CC1)C1=NC=CC(=C1)C=1OCC(N=1)C(=O)OC ZXFCJCYGLCDKTM-UHFFFAOYSA-N 0.000 description 1
- KKOUHTMLFUAAGG-UHFFFAOYSA-N methyl 2-chloropyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(Cl)=C1 KKOUHTMLFUAAGG-UHFFFAOYSA-N 0.000 description 1
- SGNCOKUHMXLGAH-UHFFFAOYSA-N methyl 6-bromopyridine-2-carboxylate Chemical compound COC(=O)C1=CC=CC(Br)=N1 SGNCOKUHMXLGAH-UHFFFAOYSA-N 0.000 description 1
- KTMKRRPZPWUYKK-UHFFFAOYSA-N methylboronic acid Chemical compound CB(O)O KTMKRRPZPWUYKK-UHFFFAOYSA-N 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000006082 mold release agent Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 229960005195 morphine hydrochloride Drugs 0.000 description 1
- XELXKCKNPPSFNN-BJWPBXOKSA-N morphine hydrochloride trihydrate Chemical compound O.O.O.Cl.O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O XELXKCKNPPSFNN-BJWPBXOKSA-N 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 229940035363 muscle relaxants Drugs 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- DYMRYCZRMAHYKE-UHFFFAOYSA-N n-diazonitramide Chemical compound [O-][N+](=O)N=[N+]=[N-] DYMRYCZRMAHYKE-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-M n-tert-butylcarbamate Chemical compound CC(C)(C)NC([O-])=O XBXCNNQPRYLIDE-UHFFFAOYSA-M 0.000 description 1
- 229960004270 nabumetone Drugs 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229960005027 natalizumab Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 208000004235 neutropenia Diseases 0.000 description 1
- 238000006396 nitration reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 1
- 229950006344 nocodazole Drugs 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- VTRAEEWXHOVJFV-UHFFFAOYSA-N olmesartan Chemical compound CCCC1=NC(C(C)(C)O)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 VTRAEEWXHOVJFV-UHFFFAOYSA-N 0.000 description 1
- 229960005117 olmesartan Drugs 0.000 description 1
- QQBDLJCYGRGAKP-FOCLMDBBSA-N olsalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=C(C(O)=CC=2)C(O)=O)=C1 QQBDLJCYGRGAKP-FOCLMDBBSA-N 0.000 description 1
- 229960004110 olsalazine Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940127084 other anti-cancer agent Drugs 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229960005118 oxymorphone Drugs 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 229960000482 pethidine Drugs 0.000 description 1
- 229960003893 phenacetin Drugs 0.000 description 1
- 229960005222 phenazone Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 125000006684 polyhaloalkyl group Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229960000688 pomalidomide Drugs 0.000 description 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 description 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 1
- 229960003081 probenecid Drugs 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 208000002815 pulmonary hypertension Diseases 0.000 description 1
- 230000006824 pyrimidine synthesis Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229960004432 raltitrexed Drugs 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 description 1
- 229950005650 reparixin Drugs 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229960001487 rimexolone Drugs 0.000 description 1
- QTTRZHGPGKRAFB-OOKHYKNYSA-N rimexolone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CC)(C)[C@@]1(C)C[C@@H]2O QTTRZHGPGKRAFB-OOKHYKNYSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940058287 salicylic acid derivative anticestodals Drugs 0.000 description 1
- 150000003872 salicylic acid derivatives Chemical class 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-M serinate Chemical compound OCC(N)C([O-])=O MTCFGRXMJLQNBG-UHFFFAOYSA-M 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 1
- AGHLUVOCTHWMJV-UHFFFAOYSA-J sodium;gold(3+);2-sulfanylbutanedioate Chemical compound [Na+].[Au+3].[O-]C(=O)CC(S)C([O-])=O.[O-]C(=O)CC(S)C([O-])=O AGHLUVOCTHWMJV-UHFFFAOYSA-J 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 229960002256 spironolactone Drugs 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 1
- 229960001940 sulfasalazine Drugs 0.000 description 1
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 1
- MBGGBVCUIVRRBF-UHFFFAOYSA-N sulfinpyrazone Chemical compound O=C1N(C=2C=CC=CC=2)N(C=2C=CC=CC=2)C(=O)C1CCS(=O)C1=CC=CC=C1 MBGGBVCUIVRRBF-UHFFFAOYSA-N 0.000 description 1
- 229960003329 sulfinpyrazone Drugs 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 description 1
- 229960000894 sulindac Drugs 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960005314 suramin Drugs 0.000 description 1
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- WZWYJBNHTWCXIM-UHFFFAOYSA-N tenoxicam Chemical compound O=C1C=2SC=CC=2S(=O)(=O)N(C)C1=C(O)NC1=CC=CC=N1 WZWYJBNHTWCXIM-UHFFFAOYSA-N 0.000 description 1
- 229960002871 tenoxicam Drugs 0.000 description 1
- YGJXBTRLYHCWGD-UHFFFAOYSA-N tert-butyl 4-(bromomethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CBr)CC1 YGJXBTRLYHCWGD-UHFFFAOYSA-N 0.000 description 1
- KXEULOGPDAWHIC-UHFFFAOYSA-N tert-butyl N-[3-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=CC(B2OC(C)(C)C(C)(C)O2)=C1F KXEULOGPDAWHIC-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-SSDOTTSWSA-N tert-butyl n-[(3r)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCNC1 DQQJBEAXSOOCPG-SSDOTTSWSA-N 0.000 description 1
- DQQJBEAXSOOCPG-ZETCQYMHSA-N tert-butyl n-[(3s)-pyrrolidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCNC1 DQQJBEAXSOOCPG-ZETCQYMHSA-N 0.000 description 1
- IOGXOCVLYRDXLW-UHFFFAOYSA-N tert-butyl nitrite Chemical compound CC(C)(C)ON=O IOGXOCVLYRDXLW-UHFFFAOYSA-N 0.000 description 1
- 239000012414 tert-butyl nitrite Substances 0.000 description 1
- DTMJYCBUOKAZBZ-UHFFFAOYSA-N tert-butyl-dimethyl-[1-(2-methyl-6-nitroindazol-5-yl)piperidin-3-yl]oxysilane Chemical compound [Si](C)(C)(C(C)(C)C)OC1CN(CCC1)C1=CC2=CN(N=C2C=C1[N+](=O)[O-])C DTMJYCBUOKAZBZ-UHFFFAOYSA-N 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229950002896 tetomilast Drugs 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- 229960003433 thalidomide Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- DUYAAUVXQSMXQP-UHFFFAOYSA-M thioacetate Chemical compound CC([S-])=O DUYAAUVXQSMXQP-UHFFFAOYSA-M 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 1
- 229960003989 tocilizumab Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 1
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 229940046728 tumor necrosis factor alpha inhibitor Drugs 0.000 description 1
- 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- ODVKSTFPQDVPJZ-UHFFFAOYSA-N urinastatin Chemical compound C1C=CCCC11COC(C=2OC=CC=2)OC1 ODVKSTFPQDVPJZ-UHFFFAOYSA-N 0.000 description 1
- 108010088854 urinastatin Proteins 0.000 description 1
- 229960003824 ustekinumab Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 229960002004 valdecoxib Drugs 0.000 description 1
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 229960004914 vedolizumab Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 210000004127 vitreous body Anatomy 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 229950004227 zaltoprofen Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 229940124629 β-receptor antagonist Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
この発明はインターロイキン1受容体関連キナーゼ(IRAK)と関連する癌および炎症疾患の治療に有用な化合物、より特定的にはIRAK−4の機能を調節する化合物に関する。発明はまた、本発明の化合物を含む薬学的に許容される組成物およびIRAK−4と関連する疾患の治療において前記組成物を使用する方法を提供する。
式中、
Z1は任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリルであり、または存在せず;
Z2は任意で置換されたシクロアルキル、任意で置換されたアリールまたは任意で置換されたヘテロシクリルであり;
R1は水素、任意で置換されたアルキル、アミノ、ハロゲン、シアノ、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R2は、各事象において、水素、ハロゲン、アミノ、任意で置換されたアルキル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R3は、各事象において、ヒドロキシル、ハロゲン、任意で置換されたアルキル、任意で置換されたアルコキシ、任意で置換されたシクロアルキルまたは−NRaRbであり;
RaおよびRbは、独立して、各事象に対し、水素、任意で置換されたアルキル、任意で置換されたアシル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
mは、各事象において、0、1または2であり;ならびに
nは、各事象において、0、1、または2である。
式中、
Z1は、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリルを表し、または存在せず;
Z2は、任意で置換されたシクロアルキル、任意で置換されたアリールまたは任意で置換されたヘテロシクリルを表し;
R1は水素、任意で置換されたアルキル、アミノ、ハロゲン、シアノ、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R2は、各事象において、アミノ、任意で置換されたアルキル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R3は、各事象においてヒドロキシル、ハロゲン、任意で置換されたアルキル、任意で置換されたアルコキシ、任意で置換されたシクロアルキルまたは−NRaRbであり;
RaおよびRbは、独立して各事象に対し、水素、任意で置換されたアルキル、任意で置換されたアシル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
mは、各事象において、0、1または2であり;ならびに
nは、各事象において、0、1、または2である。
1つのある一定の実施形態では、提供される本発明は、任意で薬学的に許容される担体または希釈剤と混合された、本明細書で開示される化合物を含む医薬組成物を提供する。
(1)疾患修飾性抗リウマチ薬(DMARD)
(a)ペニシラミン、例えばD−ペニシラミンなど。
(b)アミノサリチル酸調製物、例えばスルファサラジン、メサラジン、オルサラジン、バルサラジドなど。
(c)抗マラリア薬、例えばクロロキンなど。
(d)ピリミジン合成阻害剤、例えばレフルノミドなど。
(2)非ステロイド性抗炎症薬(NSAID)
(a)古典的NSAID、例えばトルメチン、レボルファノール、エトドラク、フェノプロフェン、メロキシカム、エテンザミド、テノキシカム、フェナセチン、メクロフェナム酸、サリチル酸、オキサプロジン、チアプロフェン酸、ロルノキシカム、ナブメトン、アセトアミノフェン、アルコフェナク(alcofenac)、ウリナスタチン、スルピリン、アンチピリン、サリチル酸ナトリウム、ミグレニン、アスピリン、メフェナム酸、フルフェナム酸、ジクロフェナクナトリウム、ヒアルロン酸ナトリウム、ロキソプロフェンナトリウム、フェニルブタゾン、インドメタシン、メシル酸カモスタット、イブプロフェン、ナプロキセン、フルルビプロフェン、フェンブフェン、プラノプロフェン、フロクタフェニン、ケトプロフェン、ピロキシカム、エピリゾール、チアラミド塩酸塩、ザルトプロフェン、メシル酸ガベキサート、アセクロフェナク、スリンダク、コルヒチン、プロベネシド、スルフィンピラゾン、ベンズブロマロン、アロプリノール、金チオリンゴ酸ナトリウム、モルヒネ塩酸塩、アトロピン、スコポラミン、モルヒネ、ペチジン、オキシモルフォンまたはその塩など。
(b)シクロオキシゲナーゼ阻害剤(COX−1選択的阻害剤、COX−2選択的阻害剤など)、例えばサリチル酸誘導体(例えば、セレコキシブ、アスピリン)、エトリコキシブ、バルデコキシブ、ジクロフェナク、インドメタシン、ロキソプロフェンなど。
(c)一酸化窒素放出NSAID
(d)JAK阻害剤、例えばルキソリチニブ、トファシチニブなど。
(3)インテグリン阻害剤、例えばナタリズマブ、ベドリズマブ、AJT300、TRK−170、E−6007など。
(4)抗サイトカイン薬
(a)TNF阻害剤、例えばインフリキシマブ、アダリムマブ、エタネルセプト、セルトリズマブペゴル、ゴリムマブ、可溶性TNF−a受容体、TNF−結合タンパク質、抗TNF−抗体など。
b)インターロイキン−1阻害剤、例えばアナキンラ(IL−1RA)、可溶性インターロイキン−1受容体など。
(c)インターロイキン−6阻害剤、例えばトシリズマブ(IL−6R)、抗インターロイキン−6抗体など。
(d)インターロイキン−10モジュレーター
(e)インターロイキン−12/23阻害剤、例えばウステキヌマブ、ブリアキヌマブ(抗インターロイキン−12/23抗体)など。
(f)MAPK阻害剤、例えばBMS−582949など。
(g)サイトカイン産生阻害剤、例えばイグラチモド、テトミラストなど。
(h)TNF−変換酵素阻害剤
(i)インターロイキン−β変換酵素阻害剤、例えばVX−765。
(j)インターロイキン−6アンタゴニスト、例えばHMPL−004。
(k)インターロイキン−8阻害剤、例えばIL−8アンタゴニスト、CXCR1&CXCR2アンタゴニスト、レパリキシンなど。
(l)ケモカインアンタゴニスト、例えばCCR9アンタゴニスト(CCX−282、CCX−025)、MCP−1アンタゴニストなど。
(m)インターロイキン−2受容体アンタゴニスト、例えばデニロイキン、ジフチトクスなど。
(n)治療ワクチン、例えばTNF−aワクチン。
(o)アンチセンス化合物、例えばISIS104838。
(5)アンジオテンシン変換酵素阻害剤、例えばエナラプリル、カプトプリル、ラミプリル、リシノプリル、シラザプリル、ペリンドプリルなど。
(6)アンジオテンシンII受容体アンタゴニスト、例えばカンデサルタン、カンデサルタンシレキセチル、アジルサルタン、アジルサルタンメドキソミル、バルサルタン、イルベサルタン、オルメサルタン、エプロサルタンなど。
(7)ステロイド、例えばデキサメタゾン、ヘキセストロール、メチマゾール、ベタメタゾン、トリアムシノロン、トリアムシノロンアセトニド、フルオシノニド,フルオシノロンアセトニド、プレドニゾロン、メチルプレドニゾロン、酢酸コルチゾン、ヒドロコルチゾン、フルオロメトロン、ジプロピオン酸ベクロメタゾン、エストリオールなど。
(8)免疫調節物質(免疫抑制剤)、例えばメトトレキサート、シクロホスファミド、MX−68、アチプリモドジヒドロクロリド、BMS−188667、CKD−461、リメキソロン、シクロスポリン、タクロリムス、グスペリムス、アザチオプリン、抗リンパ球血清、フリーズドライスルホン化正常免疫グロブリン、エリスロポエチン、コロニー刺激因子、インターロイキン、インターフェロンなど。
(9)利尿薬、例えばヒドロクロロチアジド、スピロノラクトン、フロセミド,インダパミド、ベンドロフルアジド、シクロペンチアジドなど。
(10)ジヒドロオロト酸デヒドロゲナーゼ(DHODH)阻害剤
(11)HG−CoAレダクターゼ阻害剤、アトルバスタチン、シンバスタチンなど。
(12)β受容体アンタゴニスト、例えばカルベジロール、メトプロロール、アテノロールなど。
(13)抗血小板薬、抗凝固剤、例えばヘパリン、アスピリン、ワルファリンなど。
(14)強心薬、例えばジゴキシン、ドブタミンなど。
(15)ホスホジエステラーゼIV(PDE IV)阻害剤、例えばロフルミラスト、CG−1.088など。
(16)iNOS阻害剤、例えばVAS−203など。
(17)キナーゼ阻害剤、例えば、EGFR、VEGF、Bcr−Abl、BTK、PI3K、Sykなどを標的にするもの。
ある一定の実施形態では、本発明は、薬として使用するための、化合物またはその薬学的に許容される塩もしくは立体異性体に関する。
API 2000 LC/MS/MS/Triplequad、
Agilent (1100) Technologies/LC/MS/DVL/Singlequadおよび
Shimadzu LCMS−2020/Singlequad。
中間体1
(S)−2−(3−((tert−ブトキシカルボニル)アミノ)ピロリジン−1−イル)オキサゾール−4−カルボン酸
2−クロロオキサゾール−4−カルボン酸エチル(100mg、0.5698mmol)、tert−ブチル(S)−ピロリジン−3−イルカルバメート(127mg、0.6837mmol)、DIPEA(0.284mL、1.4245mmol)およびDMF(5mL)の混合物を120℃で2時間加熱した。反応塊(reaction mass)を、氷水で反応停止させ、DCMで抽出した。溶媒を減圧下で除去して、標題化合物を得た(170mg、91.89%)。
LCMS:%、m/z=270.1(M−t−ブチル+1)。
(S)−2−(3−((tert−ブトキシカルボニル)アミノ)ピロリジン−1−イル)オキサゾール−4−カルボン酸エチル(170mg、0.5224mmol)、水酸化リチウム(33mg、0.7837mmol)を含むTHF/メタノール/水(10/1/2mL)の溶液を室温で12時間の間撹拌した。反応混合物を、2N HClで酸性化し、溶媒を蒸留し、固体を濾過し、標題化合物を得た(150mg、96.77%)。
LCMS:%、m/z=297.13.0(M−t−ブチル+1)。
(S)−2−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)オキサゾール−4−カルボン酸
標題化合物を、中間体1の工程1に記載される手順に従い、2−クロロオキサゾール−4−カルボン酸エチル(500mg、2.8490mmol)を(S)−ピロリジン−3−オール(298mg、3.4188mmol)と反応させることにより調製した。収率:535mg(83.07%);LCMS:%、m/z=227.1(M+1)。
(S)−2−(3−ヒドロキシピロリジン−1−イル)オキサゾール−4−カルボン酸エチル(535mg、2.3672mmol)を含むDMF(10mL)の溶液に、DMAP(29mg、0.2367mmol)、TBDMS塩化物(429mg、2.8407mmol)およびイミダゾール(396mg、5.8072mmol)を添加し、反応混合物を室温で2時間の間撹拌し、粗化合物を得、これを60−120シリカゲルカラムクロマトグラフィーにより、溶離液として20%酢酸エチルを含むヘキサンを使用して精製し、標題化合物を得た(520mg、64.5%)。LCMS: %, m/z = 341.2 (M+1)。
(S)−2−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)オキサゾール−4−カルボン酸エチル(520mg、1.5294mmol)の溶液を、中間体1の工程2に記載される手順に従い加水分解させ、標題化合物を得た(350mg、73.37%)。
1HNMR (CDCl3, 400MHz): δ 7.88 (s, 1H), 4.55−4.50(s, 1H), 3.75−3.60 (m, 3H), 3.5−3.4 (d, 1H), 2.05−1.90 (m, 2H), 0.9 (s, 9H). LCMS: %, m/z = 313.1 (M+1).
2−(2−アミノピリジン−4−イル)オキサゾール−4−カルボン酸
N−(5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボロラン−2−イル)ピリジン−2−イル)アセトアミド(2.78g、10.04mmol)を含む1,2−ジメトキシエタン(30ml)の溶液に、窒素下で、2−クロロオキサゾール−4−カルボン酸エチル(1g、7.09mmol)、炭酸ナトリウム(106mg、21.2mmol)を含む水(5ml)およびPd(DPPF)Cl2(259mg、0.354mmol)を添加し、90℃まで4時間の間加熱し、粗化合物を得、これを60−120シリカゲルカラムクロマトグラフィーにより、溶離液として50%酢酸エチルを含むヘキサンを使用して精製し、標題化合物を得た(680mg、36%)。LCMS:276.3(M+1)+。
2−(2−アセトアミドピリジン−4−イル)オキサゾール−4−カルボン酸エチル(中間体3の工程1の生成物)(900mg、3.27mmol)を、水酸化リチウム(329mg、7.85mmol)を含むTHF/メタノール/水(30/1/5mL)を用いて、室温で4時間の間加水分解させ、標題化合物を得た(750mg、96%)。1HNMR (DMSO−d6)、(300MHz): δ 8.15(s,1H)、8.00(d,1H)、6.972−6.90(m,2H)、6.22(s,1H) LCMS: 97.8%、m/z = 206.2 (M+1)
4−メチル−2−(2−メチルピリジン−4−イル)オキサゾール−5−カルボン酸
2−クロロ−3−オキソブタン酸エチル(20g、12.1mmol)および尿素(24g、50.0mmol)を含むメタノール(120ml)の溶液を36時間の間加熱し、還流させた。得られた固体を濾過し、2N水酸化ナトリウムに懸濁させ、酢酸エチルで抽出した。有機層をNa2SO4上で乾燥させ、減圧下で濃縮し、標題化合物を得た(1.8g、5%)。
1HNMR (DMSO−d6), (300MHz): δ7.43(s, 2H), 4.18(q, 2H), 2.22(s, 3H), 1.24(t, 3H)
LCMS: 97.75%, m/z = 171.2 (M+1)
塩化第二銅(822mg、0.611mmol)および亜硝酸tert−ブチル(578mg0.56mmol)を含むアセトニトリル(30ml)の懸濁液に2−アミノ−4−メチルオキサゾール−5−カルボン酸エチル(800mg、0.47mmol)を10℃未満で添加し、室温で2時間の間撹拌した。反応混合物を、2N HClで反応停止させた。化合物を、ジエチルエーテルで抽出し、濃縮して粗生成物を得、これをカラムクロマトグラフィーにより、10%酢酸エチルを含むヘキサンを用いて精製し、標題化合物を得た(400mg、44.9%)。LCMS: 94.66%、m/z = 190.05 (M+1)
標題化合物を、中間体3の工程1および2に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:170mg(98%)。
1HNMR (DMSO−d6), (300MHz): δ 8.65(s,1H), 7.80(s,1H), 7.71(d,1H), 3.95(bs, 1H), 2.58 (s,3H), 2.46(s,3H), LCMS: 97.8%, m/z = 206.2 (M+1), HPLC:98.4%。
(S)−6−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)ピコリン酸
6−ブロモピコリン酸(5g、2.47mmol)を含むメタノール(35ml)の溶液に、SOCl2(4.417g、3.7mmol)を0℃で添加し、2時間の間加熱し、還流させた。メタノールを減圧下で蒸発させ、化合物を酢酸エチルで抽出し、NaHCO3溶液で洗浄し、Na2SO4上で乾燥させ、濃縮し、標題化合物を得た(5.2g、91%)。
1HNMR (DMSO−d6), (300MHz): δ8.11−8.05(m, 1H) 7.99−7.91(m, 1H) 7.82−7.79(m, 1H) LCMS: 55.34%, m/z = 218.1 (M+1).
封管中に、6−ブロモピコリン酸メチル(1g、0.462mmol)、(S)−ピロリジン−3−オール(858mg、0.694mmol)、炭酸ナトリウム(1.9g、1.85mmol)およびDMF(10mL)を入れ、140℃で4時間の間加熱し、粗化合物を得、これを60−120シリカゲルカラムクロマトグラフィーにより、溶離液として1%メタノールを含むDCMを用いて精製し、標題化合物を得た(500mg、49%)。 LCMS: 97.46%、m/z = 223.2 (M+1)
標題化合物を、中間体2の工程2に記載される手順に従い、(S)−6−(3−ヒドロキシピロリジン−1−イル)ピコリン酸メチル(500mg、0.22mmol)をTBDMS塩化物(405mg、0.270mmol)と反応せさせることにより調製した。収率:400mg(52.9%)。
1HNMR (DMSO−d6), (300MHz): δ7.52(t, 1H), 7.40(d, 1H), 6.12(d, 1H), 4.54−4.52(m, 1H), 3.93(s, 3H), 3.70−3.57(m, 3H), 3.40−3.35(m, 2H) 2.09−1.96(m, 2H) 1.46(s, 3H), 0.90(s, 9H), 0.02(s, 6H)
標題化合物を、中間体2の工程3に記載される手順に従い(S)−6−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)ピコリン酸メチルを加水分解することにより調製した。収率:250mg、(66%);LCMS:95.41%、m/z=323.32(M+1)。
2−(4−(tert−ブトキシカルボニル)ピペラジン−1−イル)オキサゾール−4−カルボン酸
工程1:2−(4−(tert−ブトキシカルボニル)ピペラジン−1−イル)オキサゾール−4−カルボン酸エチルの調製
tert−ブチルピペラジン−1−カルボキシレート(637mg、3.42mmol)および2−クロロオキサゾール−4−カルボン酸エチル(500mg、2.85mmol)を含むDMF(10ml)の溶液に、K2CO3(771mg5.714mmol)を添加し、室温で5時間の間撹拌した。反応混合物を、水により反応停止させ、化合物を、酢酸エチルで抽出し、濃縮し、標題化合物を得た(380mg、41%)。LCMS:98.04%、m/z=277.2(M−tert−ブチル)。
2−(4−(tert−ブトキシカルボニル)ピペラジン−1−イル)オキサゾール−4−カルボン酸エチル(200mg、0.065mmol)、水酸化リチウム(100mg、0.24mmol)、THF/メタノール/水(10/5/5mL)の溶液を室温で2時間の間撹拌した。反応混合物を、2N HClで酸性化し、溶媒を蒸留し、固体を濾過し、標題化合物を得た(20mg、11%)。
LCMS:98.04%、m/z=298.3(M+1)。
2−(4−メチルピペラジン−1−イル)オキサゾール−4−カルボン酸
1−メチルピペラジン(1g、5.71mmol)および2−クロロオキサゾール−4−カルボン酸エチル(0.7g、6.85mmol)を含むDMF(15ml)の溶液に、K2CO3(1.5g、11.42mmol)を添加し、室温で5時間の間撹拌した。反応混合物を水により反応停止させ、化合物を酢酸エチルで抽出し、濃縮し、標題化合物を得た(450mg、33%)。LCMS:93.9%、m/z=240.3(M+1)
2−(4−メチルピペラジン−1−イル)オキサゾール−4−カルボン酸エチル(250mg、0.10mmol)、水酸化リチウム(100mg、0.24mmol)、THF/メタノール/水(10/5/5mL)の溶液を室温で2時間の間撹拌し、2N HClで酸性化し、溶媒を蒸留させ、固体を濾過し、標題化合物を得た。収率:270mg(粗)。LCMS:99.6%、m/z=212.0(M+1)。
2−(2−シクロプロピルピリジン−4−イル)オキサゾール−4−カルボン酸
2−クロロイソニコチン酸メチル(2g、1.17mmol)を含む1,4−ジオキサン(30ml)の溶液に、窒素下で、シクロプロピルボロン酸(1.5g,1.7mmol)、炭酸カリウム(2.4g、1.70mmol)を含む水(5ml)およびPd(PPh3)4(0.675g.0.050mmol)を添加し、90℃まで4時間の間加熱し、粗化合物を得、これを60−120シリカゲルカラムクロマトグラフィーにより、溶離液として50%酢酸エチルを含むヘキサンを用いて精製し、標題化合物を得た(0.8g、39.02%)。LCMS:90.3%、m/z=178.0(M+1)
2−シクロプロピルイソニコチン酸メチル(中間体9の工程1の生成物)(800mg、0.451mmol)、水酸化リチウム(284mg、0.677mmol)、THF/メタノール/水(20/10/10mL)の溶液を室温で2時間の間撹拌した。反応混合物を、2N HClで酸性化し、溶媒を蒸留し、固体を濾過し、標題化合物を得た(700mg、95.89%)。LCMS:97.66%、m/z=164.3(M+1)
2−シクロプロピルイソニコチン酸(中間体9の工程2の生成物)(700mg、0.42mmol)を含むDMF(5mL)の溶液にL−セリンメチルエステル(799mg、0.51mmol)、EDCI(1.23g、0.640mmol)、HOBt(57.9mg、0.042mmol)およびDIPEA(1.66g、1.28mmol)を添加した。反応混合物を12時間室温で撹拌した。DMFを減圧下で完全に蒸発させ、化合物を酢酸エチルで抽出し、Na2SO4上で乾燥させ、濃縮した。粗化合物をジエチルエーテルで洗浄し、標題化合物を得た(700mg、62%)。LCMS:100%、m/z=265.2(M+1)
メチル(2−シクロプロピルイソニコチノイル)セリナート(中間体9の工程3の生成物)(700mg、0.26mmol)を含むDCM(35mL)の溶液にDAST(747mg、0.463mmol)を−70℃で一滴ずつ添加し、−55℃で2時間の間撹拌した。その後、K2CO3(1.27g、0.921mmol)を添加し、反応混合物を室温で2時間の間撹拌した。過剰のK2CO3を濾過し、濾液を次の工程で精製せずに使用した。LCMS:92.56%、m/z=247.3(M+1)
2−(2−シクロプロピルピリジン−4−イル)−4,5−ジヒドロオキサゾール−4−カルボン酸メチル(中間体9の工程4の生成物)(640mg、0.260mmol)を含むDCM(35mL)の溶液に、DBU(1.19g、0.780mmol)およびBrCCl3(1.55g、0.780)を0℃で添加し、室温で2時間の間撹拌した。反応塊を、NaHCO3溶液およびブライン溶液で洗浄し、Na2SO4上で乾燥させ、カラムクロマトグラフィーにより、30%酢酸エチルを含むヘキサンを用いて精製し、標題化合物を得た(400mg、66%)LCMS:96.89%、m/z=245.1(M+1)
2−(2−シクロプロピルピリジン−4−イル)オキサゾール−4−カルボン酸メチル(中間体9の工程5の生成物)(400mg、0.155mmol)、水酸化リチウム(75mg、0.311mmol)、THF/メタノール/水(20/10/10mL)の溶液を室温で2時間の間撹拌し、反応混合物を、2N HClで酸性化した。過剰の溶媒を蒸発させ、固体を濾過し、標題化合物を得た(356mg、100%)。LCMS:100%、m/z=231.3(M+1)
2−(2−アミノ−3−フルオロピリジン−4−イル)オキサゾール−4−カルボン酸
封管中の2−ブロモ−4−クロロ−3−フルオロピリジン(825mg、3.92mmol)を含む1−4ジオキサンの溶液に(10ml)、tert−ブチルカルバメート(505mg、4.32mmol)および炭酸セシウム(2.30g、7.85mmol)およびPd(dba)(3350mg、0.392mmol)およびキサントホス(230mg、0.392mmol)をアルゴン下で添加し、反応混合物を100℃で4時間の間撹拌した。化合物を、酢酸エチルで抽出し、Na2SO4上で乾燥させ、濃縮して粗化合物を得、これをカラムクロマトグラフィーにより、20%EtOACを含むヘキサンを用いて精製し、標題化合物を得た(450mg、46.5%)。LCMS:63.4%、m/z=247.0(M+1)
tert−ブチル(4−クロロ−3−フルオロピリジン−2−イル)カルバメート(中間体14の工程1の生成物)(600mg、2.43mmol)を含む1,4−ジオキサン(10ml)の溶液に窒素下で、ビスピナカラトジボロン(Bispinacalatodiboron)(860mg、3.41mmol)、酢酸カリウム(470mg、4.87mmol)およびPd(DDPF)C12(170mg、170mmol)を添加し、100℃まで40分間加熱した。反応混合物を酢酸エチルで希釈し、EtOAc層を水により洗浄し、Na2SO4上で乾燥させ、濃縮して粗化合物を得、これを、コンビフラッシュクロマトグラフィーにより3.5%メタノールを含むクロロホルムを用いて精製し、標題化合物を得た(500mg)。
標題化合物を、中間体3の工程1および2に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:100mg(92.5%)LCMS:72.0%、m/z=224.6(M+1)。
2−(2−アミノピリジン−3−イル)オキサゾール−4−カルボン酸
2−(2−アセトアミドピリジン−4−イル)オキサゾール−4−カルボン酸
LCMS:91.64%;m/z=248.01(M+1)。
2−(1H−ピロロ[2,3−b]ピリジン−4−イル)オキサゾール−4−カルボン酸
4−クロロ−1H−ピロロ[2,3−b]ピリジン(645mg、3.28mmol)を含むトルエン(10ml)の溶液に、p−トルエンスルホニルクロリド(689mg、3.61mmol)、テトラブチルアンモニウム硫酸水素塩(55mg、0.164)およびNaOH(2g、52.63mmol)の水溶液を0℃で添加し、室温で12時間の間撹拌した。反応塊を酢酸エチルで希釈し、有機層を分離し、Na2SO4上で乾燥させ、濃縮し、粗化合物を得、これを、カラムクロマトグラフィーにより、10%EtOACを含むヘキサンを用いて精製し、標題化合物を得た(852mg、74%)。LCMS:97.8%;m/z=307.1(M+1)。
中間体14の工程2で記載されるのと同じ反応条件を用いて、4−クロロ−1−トシル−1H−ピロロ[2,3−b]ピリジン(850mg、2.43mmol)をPd(DDPF)Cl2(100mg、0.127mmol)と反応させ、標題化合物を得た(753mg、78.2%);LCMS:98.03%;m/z=399.2(M+1)。
標題化合物を、中間体3の工程1および2に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:277mg(91%);LCMS:87.82%;m/z=230.2(M−1)。
実施例1
N−(1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
4−フルオロ−2−メチル−5−ニトロアニリン(1.0gm、5.847mmol)、酢酸カリウム(690mg、7.0164mmol)および無水酢酸(1.8gm、17.543mmol)を含むクロロホルム(30mL)の混合物を、40℃で0.5時間の間加熱した。この温度で、亜硝酸イソアミル(1.37gm、11.694mmol)を添加し、80℃で12時間撹拌した。反応の完了後、溶媒を減圧下で除去し、残渣を炭酸ナトリウム溶液で塩基性化し、酢酸エチルで抽出した。有機層を水で、続いてブライン溶液で洗浄し、減圧下で濃縮し、粗化合物を得た。残渣をカラムクロマトグラフィーによりシリカゲル上で精製し(30%EtOAc:ヘキサン)、純粋化合物を得、これをメタノール性HCl(60mL)と共に30分間撹拌した。反応混合物を減圧下で濃縮し、炭酸ナトリウム水溶液で塩基性化し、酢酸エチルで抽出した。有機層を、水、ブラインで洗浄し、無水Na2SO4上で乾燥させ、減圧下で濃縮し、粗化合物を得た(130mg)。
1HNMR (DMSO−d6、300MHz): δ 13.8 (s, 1H), 8.39−8.37 (d, 1H), 8.27 (s, 1H), 7.95−7.92 (d, 1H). LCMS: m/z = 180.0 (M−1).
封管中の、5−フルオロ−6−ニトロ−1H−インダゾール(130mg、0.528mmol)およびピペリジン(0.5mL)の溶液を100℃で3時間の間撹拌した。反応の完了後、反応混合物を減圧下で濃縮し、粗標題生成物を得た(70mg)。
LCMS:90.32%、m/z=247.0(M+1)。
水素化ナトリウム(390mg、8.13mmol)を含むTHF(10mL)の溶液に、6−ニトロ−5−(ピペリジン−1−イル)−1H−インダゾール(1g、4.065mmol)を0℃で添加した。15分後、0℃でヨウ化メチル(2.3gm、16.26mmol)を添加した。反応混合物を2時間の間室温にさせた。反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをシリカゲルカラムクロマトグラフィーにより精製し、20%酢酸エチルを含むヘキサンで溶離して、異性体A;1−メチル−6−ニトロ−5−(ピペリジン−1−イル)−1H−インダゾールを得た(350mg、33.14%)
1HNMR (CDCl3、400MHz): δ 7.95 (s, 1H), 7.72 (s, 1H), 7.49 (s, 1H), 4.08 (s, 3H), 2.94−2.92 (t, 4H), 1.73−1.66 (m, 4H), 1.60−1.52 (m, 2H). LCMS: 99.15%, m/z = 261.4 (M+1).
1HNMR (CDCl3、400MHz): δ 7.97 (s, 1H), 7.85 (s, 1H), 7.29 (s, 1H), 4.22 (s, 3H), 2.92−2.89 (t, 4H), 1.72−1.66 (m, 4H), 1.59−1.54 (m, 2H).LCMS: 97.53%, m/z = 261.4 (M+1).
1−メチル−6−ニトロ−5−(ピペリジン−1−イル)−1H−インダゾール(350mg、1.346mmol)を含むTHF(20mL)の溶液に、塩化アンモニウム(1.2gm、21.536mmol)を含む水(5mL)、および亜鉛末(700mg、10768mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過し、DCM(2*100mL)で抽出し、溶媒を蒸留させ、粗化合物を得た(300mg、100%)。LCMS:99.49%、m/z=231.1(M+1)。
1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−アミン(100mg、0.434mmol)を含むDMF(5mL)の溶液に、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(89mg、0.434mmol)、EDCI(123mg、0.651mmol)、HOBt(88mg、0.651mmol)、DIPEA(168mg、1.302mmol)を添加した。反応混合物を12時間室温で撹拌した。反応の完了後、反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをその後、メタノール性HClで処理し、標題化合物を得た(75mg、38.5%)。
1HNMR (CD3OD、300MHz): δ 9.05 (s, 1H), 8.95−8.92 (d, 1H), 8.61 (s, 1H), 8.54−8.52 (d, 1H), 8.20−8.10 (m, 3H), 4.11 (s, 3H), 3.80−3.40 (bs, 4H), 2.92 (s, 3H), 2.15−2.00 (m, 4H), 1.98−1.60 (bs, 2H). LCMS: 98.29%, m/z = 417.2 (M+1).HPLC: 98.07%.
N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
標題化合物を、実施例1の工程4に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:430mg(97.7%)。LCMS:100%、m/z=231.2(M+1)。
標題化合物を、実施例1の工程5に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:100mg(51.2%)。
1HNMR (CD3OD、300MHz): δ 9.02 (s, 1H), 8.96−8.94 (d, 1H), 8.60 (s, 1H), 8.56 (s, 1H), 8.52−8.46 (d, 1H), 8.10−7.90 (bs, 1H), 4.32 (s, 3H), 3.80−3.40 (bs, 4H), 2.91 (s, 3H), 2.10−1.95 (m, 4H), 1.90−1.65 (bs, 2H). LCMS: 99.07%, m/z = 417.2 (M+1). HPLC: 97.47%.
(S)−6−(3−ヒドロキシピロリジン−1−イル)−N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)ピコリンアミド
2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−アミン(250mg、1.08mmol)を含むDMF(5mL)の溶液に6−ブロモピコリン酸(263mg、1.30mmol)、EDCI(311mg、1.63mmol)、HOBt(154mg、1.14mmol)およびDIPEA(420mg、3.26mmol)を添加した。反応混合物を12時間室温で撹拌した。反応の完了後、反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。減圧下で濃縮した後、残渣をフラッシュクロマトグラフィー(CH2Cl2:MeOH:98.5:1.5)により精製し、標題化合物を得た(300mg、66.6%)。LCMS:94.61%、m/z=414.1(M+).HPLC:92.21%。
封管中に、6−ブロモ−N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)ピコリンアミド(100mg、0.241mmol)、(S)−ピロリジン−3−オール(32mg、0.362mmol)、炭酸ナトリウム(102mg、0.966mmol)およびDMF(4mL)を入れ、140℃で4時間の間加熱し、粗生成物を得た。精製を、60−120シリカゲルカラムクロマトグラフィーにより、溶離液として1%メタノールを含むDCMを用いて実施し、標題化合物を得た(60mg、60%)。
1HNMR (CDCl3、400MHz): δ 10.94 (s, 1H), 8.90 (s, 1H), 7.74 (s, 1H), 7.64−7.62 (m, 2H), 7.29 (s, 1H), 6.56−6.54 (dd, 1H), 4.68 (s, 1H), 4.17 (s, 3H), 3.76−3.73 (m, 4H), 3.20−2.60 (bs, 4H), 2.24−2.15 (m, 2H), 1.90−1.75 (m, 6H). LCMS: 100%, m/z = 421.4 (M+1). HPLC: 95.03%.
(S)−2−(3−アミノピロリジン−1−イル)−N−(1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−アミン(実施例1の工程4の生成物)を含むDMF(3mL)の溶液に、(S)−2−(3−((tert−ブトキシカルボニル)アミノ)ピロリジン−1−イル)オキサゾール−4−カルボン酸(中間体1)(154mg、0.521mmol)、EDCI(124mg、0.652mmol)、HOBt(88mg、0.652mmol)およびDIPEA(223mg、1.736mmol)を添加した。反応混合物を12時間室温で撹拌した。反応の完了後、反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させ、減圧下で濃縮し、粗生成物を得た。粗生成物をDCM(10mL)に溶解し、TFA/DCM(1/1mL)を添加し、室温で3時間撹拌した。反応の完了後、過剰の溶媒を減圧下で除去し、飽和炭酸ナトリウム溶液で塩基性化し、酢酸エチルで希釈した。有機層をブラインで洗浄し、無水Na2SO4上で乾燥させた。濃縮後、残渣をカラムクロマトグラフィー(CH2Cl2:MeOH;98:2)により精製し、標題化合物を得た(90mg、56.2%)。
1HNMR (CDCl3、400MHz): δ 10.5 (s, 1H), 8.64 (s, 1H), 7.84 (s, 2H), 7.43 (s, 1H), 4.04 (s, 3H), 3.76−3.74 (m, 3H), 3.70−3.60 (m, 1H), 3.31−3.29 (m, 1H), 3.10−3.00 (m, 2H), 2.80−2.65 (m, 2H), 2.30−2.20 (m, 1H), 2.10−1.70 (m, 6H). LCMS: 98.97%, m/z = 410.2 (M+1). HPLC: 96.41%.
(S)−2−(3−アミノピロリジン−1−イル)−N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、400MHz): δ 10.40 (s, 1H), 8.82 (s, 1H), 7.85 (s, 1H), 7.73 (s, 1H), 7.29 (s, 1H), 4.16 (s, 3H), 3.80−3.70 (m, 3H), 3.65−3.58 (m, 1H), 3.29−3.27 (d, 1H), 3.20−3.00 (m, 2H), 2.80−2.60 (bs, 2H), 2.30−2.15 (m, 2H), 2.00−1.75 (m, 6H). LCMS: 99.64%, m/z = 410.2 (M+1). HPLC: 96.59%.
(S)−2−(3−ヒドロキシピロリジン−1−イル)−N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、300MHz): δ 10.37 (s, 1H), 8.81 (s, 1H), 7.85 (s, 1H), 7.72 (s, 1H), 7.28 (s, 1H), 4.63 (s, 1H), 4.16 (s, 3H), 3.74−3.67 (m, 3H), 3.67−3.56 (m, 1H), 3.15−2.95 (bs, 2H), 2.80−2.60 (bs, 2H), 2.18−2.11 (m, 3H), 2.00−1.70 (m, 6H).
LCMS:96.85%、m/z=411.2(M+1).HPLC:95.08%。
(S)−6−(3−アミノピロリジン−1−イル)−N−(2−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)ピコリンアミド
1HNMR (CDCl3、400MHz):δ 10.90 (s, 1H), 7.76 (s, 1H), 7.65−7.64 (m, 2H), 7.32 (s, 1H), 6.56−6.54 (m, 1H), 4.19 (s, 3H), 3.89−3.87 (m, 1H), 3.82−3.79 (t, 2H), 3.70−3.65 (m, 2H), 3.51−3.49 (m, 1H), 3.40−3.39 (m, 2H), 2.29−2.28 (m, 2H), 1.90−1.75 (m, 7H).
LCMS:98.52%、m/z=420.3(M+1).HPLC:97.46%。
(S)−6−(3−アミノピロリジン−1−イル)−N−(1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−イル)ピコリンアミド
標題化合物を、実施例3の工程1に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。収率:700mg(90.4%)。LCMS:95.68%、m/z=414.1(M+1)
標題化合物を実施例3および実施例4の工程2の生成物に記載される手順に従い、適切な反応物および反応条件を使用することにより調製した。6−ブロモ−N−(1−メチル−5−(ピペリジン−1−イル)−2H−インダゾール−6−イル)ピコリンアミド(400mg、0.966mmol)、tert−ブチル(S)−ピロリジン−3−イルカルバメート(270mg、1.44mmol)、炭酸ナトリウム(409mg、3.86mmol)およびDMF(6mL)を140℃で4時間の間加熱した。反応を、氷水で停止させ、酢酸エチルで抽出し、Na2SO4上で乾燥させ、減圧下で濃縮し、粗生成物を得た(140mg、28%)。粗生成物をDCMに溶解し(10mL)、この溶液にTFA/DCM(1/1mL)を添加し、室温で3時間の間撹拌し、標題化合物を得た(50mg、44.24%)。
1HNMR (DMSO−d6、400MHz): δ 10.95 (s, 1H), 8.67 (s, 1H), 7.96−7.83 (m, 3H), 7.83−7.79 (t, 1H), 7.62 (s, 1H), 7.53−7.51 (d, 1H), 6.85−6.83 (d, 1H), 4.03 (s, 1H), 3.99 (s, 3H), 3.83−3.69 (m, 3H), 2.85 (s, 4H), 2.12−2.08 (m, 1H), 1.76−1.75 (m, 4H), 1.59 (bs, 2H). LCMS: 95.4%, m/z = 420.2 (M+1). HPLC: 96.29%.
(S)−6−(3−ヒドロキシピロリジン−1−イル)−N−(1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−イル)ピコリンアミド
1HNMR (CDCl3、400MHz): δ 11.1 (s, 1H), 8.79 (s, 1H), 7.87 (s, 1H), 7.70−7.64 (m, 2H), 7.49 (s, 1H), 6.62−6.59 (dd, 1H), 4.70 (s, 1H), 4.08 (s, 3H), 3.84−3.79 (m, 4H), 3.20−2.70 (bs, 4H), 2.29−2.17 (m, 3H), 1.90−1.80 (m, 6H). LCMS: 99.0%, m/z = 421.5 (M+1). HPLC: 97.08%.
(S)−2−(3−ヒドロキシピロリジン−1−イル)−N−(1−メチル−5−(ピペリジン−1−イル)−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR(CDCl3、300MHz):δ 10.52 (s, 1H), 8.63 (s, 1H), 7.85 (s, 1H), 7.83 (s, 1H), 7.43 (s, 1H), 4.65 (s, 1H), 4.04 (s, 3H), 3.76−3.61 (m, 4H), 3.10−2.90 (bs, 2H), 2.80−2.60 (bs, 2H), 2.25−2.10 (m, 3H), 2.0−1.70 (m, 6H). HPLC: 96.45%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
4−フルオロ−2−メチルアニリン(12g、96mmol)を含む濃H2SO4(110ml)の溶液を0℃まで冷却し、KNO3(10.6g、105.6mmol)を添加し、室温で1時間の間撹拌した。反応塊を水で希釈し、20%NaOHで塩基性化した。化合物を、酢酸エチルで抽出し、Na2SO4上で乾燥させ、濃縮し、標題化合物を得た(15g、81.9%)。
1HNMR(CDCl3、300MHz):δ7.61(d,1H),7.34(d,1H),2.24(s,3H).
4−フルオロ−2−メチル−5−ニトロアニリン(11g、64.32mmol)、炭酸カリウム(35.5g、257.30mmol)および(S)−ピロリジン−3−オール(8.7g、70.76mmol)を含むTHFの溶液を70℃で12時間の間撹拌した。反応混合物を濾過し、濾液を50%酢酸エチルを含むヘキサンを用いたカラムクロマトグラフィー溶離により精製し、標題化合物を得た(11g、72.3%)。LCMS:97.15%m/z=238.3(M+1)。
(S)−1−(4−アミノ−5−メチル−2−ニトロフェニル)ピロリジン−3−オール(2g、8.43mmol)(実施例11の工程2の生成物)を含むクロロホルム(50ml)の溶液に、酢酸カリウム(992mg、10.12mmol)、無水酢酸(2.58g、25.314mmol)を添加し、40℃で30分間撹拌した。亜硝酸イソアミル(1.98g、16.87mmol)を40℃で添加し、60℃まで12時間の間加熱した。反応塊を最高pH9まで塩基性化した。化合物を、重炭酸ナトリウム溶液をクロロホルムと共に用いて抽出し、Na2SO4上で乾燥させ、濃縮し、2%メタノールを含むジクロロメタンを用いたカラムクロマトグラフィー溶離により精製した。これをその後、メタノール性HClで処理し、標題化合物を得た(480mg、20.2%)。
1HNMR (CDCl3、300MHz): δ 8.02 (s,1H),7.88 (s,1H),7.22 (s,1H),4.65−4.60 (m,1H),3.57−3.51 (m,4H) 3.26−3.21 (m,1H),2.98(d,1H),2.22−2.05 (m,4H);LCMS:71.1%,m/z= 249.15(M+1).
(S)−1−(6−ニトロ−1H−インダゾール−5−イル)ピロリジン−3−オール(実施例11の工程3の生成物)(650mg、2.33mmol)を含むDMF(10mL)の溶液に、DMAP(319mg、2.62mmol)、TBDMS塩化物(790mg、5.24mmol)およびイミダゾール(267mg、3.930mmol)を添加し、室温で2時間の間撹拌し、粗生成物を得た。60−120シリカゲルカラムクロマトグラフィーにより、溶離液として20%酢酸エチルを含むヘキサンを使用して精製を実施し、標題化合物を得た(680mg、78%).LCMS:70.9%m/z=363.15(M+1)。
水素化ナトリウム(255mg、5.313mmol)を含むTHF(50mL)の溶液に、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例11の工程4の生成物)(1.3g、3.54mmol)を0℃で添加した。15分後、その溶液に0℃でヨウ化メチル(1.01g、7.084mmol)を添加した。反応混合物を2時間の間室温にさせた。反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをシリカゲルカラムクロマトグラフィーにより精製し、20%酢酸エチルを含むヘキサンで溶離して、異性体A:(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−2−メチル−6−ニトロ−2H−インダゾール(700mg、48.2%)を得た。50%酢酸エチルを含むヘキサンを用いた溶離により、異性体B:S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−6−ニトロ−1H−インダゾール(500mg、37.5%)を得た。
1HNMR (CDCl3、300MHz): δ 7.90 (s,1H) 7.80 (s,1H) 7.17 (s,1H) 4.5 (m,1H) 4.06 (s,3H) 3.50−3.30 (m,3H) 2.90−2.83 (m,1H) 2.12−1.96 (m,2H) 0.85 (s,9H) 0.1(s,6H)LCMS:93.36% m/z= 377.20(M+1).
(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−6−ニトロ−1H−インダゾール(実施例11の工程5異性体−Bの生成物)(500mg、1.32mmol)を含むTHF(20mL)の溶液に、塩化アンモニウム(1.15g、21.20mmol)を含む水(5mL)および亜鉛末(691mg、10.63mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過し、化合物を酢酸エチルで抽出し、溶媒を蒸留させ、標題化合物を得た(450mg、97.8%)。LCMS:88.2%m/z=347.25(M+1)。
(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−1H−インダゾール−6−アミン(実施例11の工程6の生成物)(200mg、0.576mmol)を含むDMF(8mL)の溶液に、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(118mg、0.576mmol)、HATU(328mg、864mmol)、DIPEA(297mg、2.304mmol)を添加した。反応混合物を12時間の間室温で撹拌した。反応の完了後、反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをその後、メタノール性HClで処理し、標題化合物を得た(120mg、61.2%)。
1HNMR (CDCl3、400MHz): δ 10.6 (s, 1H), 8.61 (s, 1H), 8.43 (s, 1H), 7.88 (d, 2H), 7.78 (d, 1H), 7.57 (s, 1H), 4.62 (bs, 1H), 4.09 (s, 3H), 3.44−3.41 (m,1H), 3.24 (d, 1H), 3.16−3.12 (m, 1H), 3.04−2.97 (m, 1H), 2.68 (s, 3H), 2.62−2.52 (m, 2H), 2.17−2.12 (m, 1H). LCMS: 100%, m/z = 419.1 (M+1). HPLC: 97.12%.
N−(5−(3−ヒドロキシピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (DMSO−d6、400MHz): δ. 10.7 (s, 1H), 9.05 (s, 1H), 8.73 (d, 1H), 8.54 (s, 1H), 7.94 (s, 1H), 7.88 (s, 1H), 7.77 (d, 1H), 7.67 (s, 1H), 4.93 (bs, 1H), 4.08 (s, 3H), 3.06 (d, 1H), 2.86−2.85 (m, 1H), 2.71−2.70 (m, 1H), 2.61 (s, 3H), 2.08−2.07 (m, 2H), 1.93−1.90 (m, 2H), 1.45−1.35 (m, 2H). LCMS: 100%, m/z = 433.1 (M+1). HPLC: 97.59%
N−(5−(3−ヒドロキシピペリジン−1−イル)−2−メチル−2H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
標題化合物を実施例11の工程6に記載される手順に従い、5−(3−((tert−ブチルジメチルシリル)オキシ)ピペリジン−1−イル)−2−メチル−6−ニトロ−2H−インダゾール(300mg、0.769mmol)を使用することにより、同じ反応条件下で調製した。収率:200mg(73.52%);LCMS:84.2%、m/z=361.41(M+1)
実施例11の工程7で記載されるのと同じ反応条件を用いて、5−(3−((tert−ブチルジメチルシリル)オキシ)ピペリジン−1−イル)−2−メチル−2H−インダゾール−6−アミン(170mg、0.471mmol)を含むDMF(8mL)、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(105mg、0.518mmol)、HATU(268mg、0.070mmol)、DIPEA(243mg、1.8mmol)を添加した。反応混合物を12時間の間室温で撹拌した。反応塊を氷により反応停止させ、固体を濾過した。これをその後、メタノール性HClで処理し、標題化合物を得た(140mg、86.5%)。
1HNMR (DMSO−d6、400MHz): δ. 10.7 (s, 1H), 9.05 (s, 1H), 8.73 (d, 1H), 8.55 (s, 1H), 8.22 (s, 1H), 7.88 (s, 1H), 7.77 (d, 1H), 7.54 (s, 1H), 4.93 (bs, 1H), 4.12 (s, 3H), 4.00 (s, 1H), 3.08−3.07 (m, 2H), 2.40−2.35 (m, 1H), 2.67−2.61 (m, 1H), 2.61 (s, 3H), 2.18−2.08 (m, 2H), 1.95−1.90 (m, 2H). LCMS: 100%, m/z = 433.1 (M+1). HPLC: 95.20%.
N−(5−(3−フルオロピペリジン−1−イル)−2−メチル−2H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
実施例11の工程2で記載されるのと同じ反応条件を用いて、1−(4−アミノ−5−メチル−2−ニトロフェニル)ピペリジン−3−オール(8g、31.8mmol)を含むクロロホルム(100ml)、酢酸カリウム(3.7g、38.0mmol)、無水酢酸(9.75g、96.0mmol)を添加し、反応混合物を40℃で30分間撹拌した。その後、亜硝酸イソアミル(7.45g、63mmol)を40℃で添加し、60℃まで12時間の間加熱した。反応塊をpH-9まで重炭酸ナトリウム溶液を用いて塩基性化させた。化合物を、クロロホルムで抽出し、Na2SO4上で乾燥させ、濃縮して粗生成物を得、これをカラムクロマトグラフィーにより、溶離液として2%メタノールを含むジクロロメタンを用いて精製し、標題化合物を得た(4g、41.0%).LCMS:76.4%、m/z=305.3(M−1)。
1−(5−(3−ヒドロキシピペリジン−1−イル)−6−ニトロ−1H−インダゾール−1−イル)エタン−1−オン(実施例14の工程1の生成物)(3.7g、12.0mmol)を含むジクロロメタン(30ml)の溶液を−70℃まで冷却し、DAST(3.3g、20.0mmol)を含むジクロロメタン(10ml)を添加し、反応混合物を−50℃で2時間の間撹拌した。反応塊をNaHCO3溶液により反応停止させ、化合物を、DCMで抽出し、Na2SO4上で乾燥させた。過剰の溶媒を減圧下で蒸発させ、化合物をカラムクロマトグラフィーにより、10%のEtOACを含むヘキサンを用いて精製した。これをその後、メタノール性HClで処理し、標題化合物を得た(1.4g、63.6%)。LCMS:81.4%、m/z=307.15(M−1)。
標題化合物を、工程5実施例11に記載される手順に従い、5−(3−フルオロピペリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例14の工程2の生成物)を使用することにより、同じ反応条件下で調製した。収率:400mg(31.7%)。
1HNMR (CDCl3、300MHz): δ.8.02(s,1H) 7.89(s,1H) 7.37(s,1H) 4.72−4.60(m,1H) 4.23(s,1H) 3.50−3.40(m,1H) 3.10−3.00(m,1H) 2.95−2.85(m,1H) 2.75−2.65(m,1H) 2.20−2.10(m,1H) 1.95−1.85(m,1H) 1.25−1.10(m,2H). LCMS: 99.25%, m/z = 279.1 (M+1).
標題化合物を、工程6実施例11に記載される手順に従い、5−(3−フルオロピペリジン−1−イル)−2−メチル−6−ニトロ−2H−インダゾール(実施例14の工程3異性体−Bの生成物)(400mg、1.4mmol)を使用することにより、同じ反応条件下で調製した。収率:300mg(83.8%);LCMS:85.88%、m/z=249.3(M+1)。
実施例11の工程7で記載されるのと同じ反応条件を用いて、5−(3−フルオロピペリジン−1−イル)−2−メチル−2H−インダゾール−6−アミン(100mg、0.400mmol)を含むDMF(8mL)を、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(98mg、0.48mmol)と反応させ、標題化合物を得た(50mg、28.4%)。
1HNMR (CDCl3、400MHz): δ 10.8 (bs, 1H), 8.87 (s, 1H), 8.69 (d, 1H), 8.41 (s, 1H), 8.0−7.8 (m, 3H), 7.38 (s, 1H), 5.0 (d, 1H), 4.20 (s, 3H), 3.50−3.49 (m, 1H), 3.20−3.00 (m, 2H),2.68 (s, 3H), 2.55−2.45 (m, 1H), 2.10−2.0 (m, 2H), 1.80− 1.70 (m, 2H).LCMS: 99.35%, m/z = 435.3 (M+1). HPLC: 99.42%.
((S)−2−(2−アセトアミドピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、300MHz): δ 10.6 (s, 1H), 8.91 (s, 1H), 8.66 (s, 1H), 8.45−8.40 (m, 2H), 8.15 (s, 1H), 7.87(s, 1H), 7.67 (d, 1H), 7.54 (s, 1H), 4.76 (bs, 1H), 4.08 (s, 3H), 3.78 (s, 1H), 3.55−3.45 (m, 1H), 3.40−3.30 (m, 1H), 3.30−3.20 (m, 2H), 3.00−2.90 (m, 1H), 2.60−2.50 (m, 1H), 2.28 (s, 3H). LCMS: 94.78%, m/z = 462.20 (M+1). HPLC: 95.02%.
N−(5−(3−フルオロピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
標題化合物を、工程6実施例11に記載される手順に従い、5−(3−フルオロピペリジン−1−イル)−1−メチル−6−ニトロ−1H−インダゾール(実施例14の工程3異性体−Aの生成物)(400mg、1.4mmol)を使用することにより、同じ反応条件下で調製した。収率:300mg(83.8%);LCMS:85.88%、m/z=249.3(M+1)。
実施例11の工程7で記載されるのと同じ反応条件を用いて、5−(3−フルオロピペリジン−1−イル)−1−メチル−1H−インダゾール−6−アミン(100mg、0.400mmol)を、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸と反応させ、標題化合物を得た(50mg、28.5%)。
1HNMR(CDCl3、400MHz):δ10.9(bs,1H),8.68(s,2H),8.40(s,1H),7.96−7.70(m,3H),7.51(s,1H),5.0(d,1H),4.08(s,3H),3.50−3.30(m,1H),3.20−3.00(m,2H),2.90−2.70(m,1H),2.68(s,3H),2.50−2.30(m,2H),2.15−1.95(m,1H),1.851.70(m,1H).
LCMS:100%、m/z=436.0(M+1).HPLC:98.45%.
N−(5−(4−ヒドロキシピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、300MHz): δ 10.80 (s, 1H), 9.06 (s, 1H), 8.66 (d, 1H), 8.51 (s, 1H), 7.80 (d, 2H), 7.78 (d, 1H), 7.64 (s, 1H), 4.97 (bs, 1H), 3.98 (s, 3H), 3.80−3.70 (m, 1H), 3.05−2.95 (m, 2H), 2.90−2.80 (m, 3H), 2.60 (s, 2H), 2.10−1.85 (m, 4H). LCMS: 100%, m/z = 433.7 (M+1). HPLC: 96.73%.
(S)−2−(2−アミノピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、300MHz): δ10.6 (s, 1H), 8.61 (S, 1H), 8.39 (s, 1H), 8.25 (d, 1H), 7.87 (d, 1H), 7.56 (s, 1H), 7.28 (d, 2H), 4.75−4.60 (m, 3H), 4.08 (s, 3H), 3.50−3.40 (m, 1H), 3.30−3.20 (m, 2H), 3.00−2.90 (m, 2H), 2.60−2.50 (m, 1H), 2.30−2.20 (m, 1H).LCMS: 100%, m/z = 420.0 (M+1). HPLC: 95.56%.
N−(5−(4−フルオロピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.6 (s, 1H), 9.11 (s, 1H), 9.70 (d, 1H), 8.55 (s, 1H), 7.95 (s, 1H), 7.86 (s, 1H), 7.60 (d, 1H), 7.70 (s, 1H), 5.05−4.90 (m, 1H),4.01 (s, 3H), 3.10−3.00 (m, 2H), 2.93−2.89 (m, 2H), 2.59 (s, 3H), 2.30−2.10 (m, 4H).LCMS: 96.6%, m/z = 435.3 (M+1). HPLC: 97.9%.
N−(5−(4−(ヒドロキシメチル)ピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、400MHz): δ 10.60 (s, 1H), 8.70 (d, 1H), 8.66 (s, 1H), 8.43 (s, 1H), 7.88 (s, 1H), 7.82 (s, 1H), 7.80 (d, 1H), 7.52 (s, 1H), 4.08 (s, 3H), 3.72 (s, 2H), 3.16 (d, 2H), 2.83 (t, 2H), 2.70 (s, 3H), 2.05−1.95 (m, 2H), 1.85−1.75 (m, 3H), 1.52−1.48 (m, 1H).LCMS: 98.77%, m/z = 447.4 (M+1). HPLC: 96.07%.
(S)−2−(2,6−ジメチルピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.43 (s, 1H), 9.02 (s, 1H), 8.45 (s, 1H), 7.88 (s, 1H), 7.68 (s, 2H), 7.63 (s, 1H), 5.08 (d, 1H), 4.51 (bs, 1H), 3.96 (s, 3H), 3.30−3.19 (m, 1H), 2.96−2.92 (m, 2H), 2.46 (s, 6H), 2.35−2.25 (m, 1H), 2.00−1.85 (m, 1H). LCMS: 100%, m/z = 433.1 (M+1). HPLC: 98.64%.
(R)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.41 (S, 1H), 9.07 (s, 1H), 8.69 (d, 1H), 8.49(s, 1H), 7.92 (d, 2H), 7.82 (d, 1H), 7.67 (s, 1H), 5.12 (bs, 1H), 4.54 (bs, 1H), 4.00 (s, 3H), 3.35 −3.22 (m, 2H), 3.01−2.96 (m, 2H), 2.60 (s, 3H), 2.36−2.31 (m, 1H), 2.00−1.90 (m, 1H).LCMS: 100%, m/z = 419.3 (M+1). HPLC: 95.60%
(S)−2−(2−アミノピリジン−3−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.5 (bs, 1H), 9.10 (s, 1H), 8.90−8.70 (bs, 2H), 8.62 (d, 1H), 8.31 (d, 1H), 8.10−8.02 (m, 2H), 7.70−7.60 (bs, 1H), 7.08 (t, 1H), 4.50−4.40 (m, 2H), 4.02 (s, 3H), 3.60−3.45 (m, 2H), 3.20−3.10 (m, 1H), 2.24−2.18 (m, 1H), 1.95−1.85 (m, 1H), 1.21 (d, 1H).
LCMS: 100%, m/z = 420.2 (M+1). HPLC: 92.37%.
6−((S)−3−ヒドロキシピロリジン−1−イル)−N−(5−((R)−3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)ピコリンアミド
1HNMR (DMSO−d6、300MHz): δ 11.04 (s, 1H), 8.67 (s, 1H), 7.91 (s, 1H), 7.74 (t, 1H), 7.67 (s, 1H), 7.38 (d, 1H), 6.73 (d, 1H), 5.07 (bs, 1H), 4.45 (bs, 2H), 3.99 (s, 3H), 3.70−3.65 (m, 2H), 3.55−3.50 (m, 2H), 3.40−3.20 (m, 4H), 2.86 (dd, 1H), 2.20−2.15 (m, 2H), 2.00−1.80 (m, 2H)
LCMS: 97.7%, m/z = 423.4 (M+1). HPLC: 98.08%.
6−((S)−3−ヒドロキシピロリジン−1−イル)−N−(5−((S)−3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)ピコリンアミド
1HNMR (DMSO−d6、400MHz): δ 11.04 (s, 1H), 8.67 (s, 1H), 7.91 (s, 1H), 7.74 (t, 1H), 7.67 (s, 1H), 7.39 (d, 1H), 6.73 (d, 1H), 5.04 (bs, 1H), 4.45 (bs, 2H), 3.99 (s, 3H), 3.60−3.50 (m, 5H), 3.35−3.25 (m, 2H), 3.15−3.10 (m, 1H), 2.83 (dd, 1H), 2.20−2.15 (m, 2H), 2.00−1.80 (m, 2H) LCMS: 96.6%, m/z = 423.4 (M+1). HPLC: 97.80%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(1H−ピロロ[2,3−b]ピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、300MHz): δ 12.13 (s, 1H), 10.40 (s, 1H), 9.09 (s, 1H), 8.56 (s, 1H), 8.44 (d, 1H), 7.94 (s, 1H), 7.78−7.72 (m, 3H), 7.20 (s, 1H), 5.10 (d, 1H), 4.60−4.55 (m, 1H), 4.01 (s, 3H), 3.49 (q, 1H), 3.34−3.25 (m, 1H), 3.20−3.10 (m, 1H), 2.92 (dd, 1H), 2.40−2.25 (m, 1H), 2.00−1.90 (m, 1H);LCMS: 85.4%, m/z = 443.9 (M+1). HPLC: 99.46%
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール(工程3実施例22の生成物)(2.1g、7.16mmol)を含むTHF(20mL)の溶液に、塩化アンモニウム(6.13g、114mmol)を含む水(5mL)および亜鉛末(3.74g、57.3mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過した。化合物を、酢酸エチルで抽出し、溶媒を蒸留して除去し、標題化合物を得た(1.92g、100%)。LCMS:75.94%、m/z=333.30(M+1)
実施例11の工程7で記載されるのと同じ反応条件を用いて、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1H−インダゾール−6−アミン(実施例27の工程1)(150mg、0.451mmol)を2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(101mg、0.496mmol)と反応させ、標題化合物を得た(35mg、18.99%)。
1HNMR (DMSO−d6、400MHz): δ 9.29 (s, 1H), 8.69 (d, 1H), 8.23 (s, 1H), 7.89 (s, 1H), 7.80 (d, 1H), 7.70 (s, 1H), 7.31 (s, 1H), 5.67 (d, 2H), 4.92 (d, 1H), 4.36−4.33 (m, 1H), 3.25−3.15 (m, 2H), 2.95−2.85 (m, 2H), 2.60 (s, 3H), 2.20−2.15 (m, 1H), 1.80−1.70 (m, 1H). LCMS: 100%, m/z = 405.3 (M+1). HPLC: 95.19%.
(S)−2−(2−アミノ−3−フルオロピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.32 (s, 1H), 9.08 (s, 1H), 8.50 (s, 1H), 7.91 (d, 1H), 7.67 (s, 1H), 7.16 (t, 1H), 6.65 (s, 1H), 5.03 (d, 1H), 4.55−4.50 (m, 1H), 4.00 (s, 3H), 3.17 (d, 2H), 3.05−3.00 (m, 1H), 2.92−2.88 (m, 1H), 2.32−2.28 (m, 1H), 1.95−1.85 (m, 1H). LCMS: 97.6%, m/z = 438.1 (M+1). HPLC: 97.41%.
(R)−2−(2−アミノピリジン−3−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CDCl3、400MHz): δ 8.60−8.50 (m, 2H), 8.25−8.15 (m, 1H), 7.97 (d, 2H), 7.65 (s, 1H), 6.94 (s, 1H), 4.05−3.95 (m, 2H), 3.55−3.45 (m, 1H), 3.25 (s, 6H), 2.40−2.30 (m, 1H), 2.20−2.10 (m, 1H). LCMS: 100%, m/z = 420.3 (M+1). HPLC: 95.61%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(4−メチルピペラジン−1−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CDCl3、300MHz): δ 10.2 (s, 1H), 7.85−7.84 (m, 2H), 7.49 (s, 1H), 4.5 (bs, 1H), 4.05 (s, 3H), 3.60−3.57 (m, 4H), 3.40−3.30 (m, 1H), 3.16 (d, 1H), 3.03−2.92 (m, 2H), 2.70 (d, 1H), 2.51 (t, 4H), 2.50−2.40 (m, 2H), 2.34 (s, 3H), 2.05−1.95 (m, 1H). LCMS: 100%, m/z = 427.0 (M+1). HPLC: 98.83%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(ピペラジン−1−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CDCl3、300MHz): δ 10.2 (s, 1H), 8.56 (s, 1H), 7.86 (d, 2H), 7.49 (s, 1H),4.5 (bs, 1H), 4.05 (s, 3H), 3.60−3.50 (m, 4H), 3.40−3.30 (m, 1H), 3.20 (d, 1H), 3.03−2.92 (m, 6H), 2.50−2.40 (m, 1H), 2.10−1.95 (m, 2H). LCMS: 98.6%, m/z = 412.6 (M+1). HPLC: 96.01%.
(S)−N−(1−エチル−5−(3−ヒドロキシピロリジン−1−イル)−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
標題化合物を、実施例11の工程5に記載される手順に従い、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例11の工程04の生成物)(400mg、1.1mmol)を使用することにより、同じ反応条件下で調製した。収率:300mg(69.9%)。LCMS:66.2%、m/z=391.4(M+1)。
標題化合物を実施例11の工程6に記載される手順に従い、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−エチル−6−ニトロ−1H−インダゾール(300mg、0.77mmol)を使用することにより、同じ反応条件下で調製した。収率:200mg(72.2%)。LCMS:92.5%、m/z=361.7(M+1)
実施例11の工程7で記載されるのと同じ反応条件を用いて、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−エチル−1H−インダゾール−6−アミン(200mg、0.6mmol)を2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(中間体4)(136mg、0.660mmol)と反応させた。これをさらにメタノール性HClで処理し、標題化合物を得た。収率:100mg(62.50%)。
1HNMR (CD3OD、400MHz): δ 8.99 (s, 1H), 8.91 (d, 1H), 8.64 (s, 1H), 8.55 (d, 1H), 8.4−8.3 (bs, 1H), 8.18 (s, 1H), 8.0−7.9 (s, 1H), 4.74 (s, 1H), 4.51 (q, 2H), 4.0−3.9 (m, 3H), 3.66 (d, 1H), 2.92 (s, 3H), 2.50−2.30 (m, 2H), 1.49 (t, 3H).LCMS: 92.3%, m/z = 433.3 (M+1). HPLC: 97.97%.
(S)−N−(1−シクロプロピル−5−(3−ヒドロキシピロリジン−1−イル)−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例11の工程04の生成物)(600mg、1.6mmol)、シクロプロピルボロン酸(280mg、3.3mmol)、酢酸銅(300mg、0.16mmol)、2,2’−ビピリジン(260mg、1.6mmol)を含むEDC(15ml)の溶液を、70℃で2時間の間加熱した。反応混合物をセライト(登録商標)上で濾過し、濾液を濃縮した。これをシリカゲルカラムクロマトグラフィーにより精製し、10%酢酸エチルを含むヘキサンを用いて溶離し、非極性異性体として標題化合物を得た(500mg、77.6%)。LCMS:98.60%、m/z=403.0(M+1)。
実施例11の工程6で記載される同じ反応条件を用いて、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−シクロプロピル−6−ニトロ−1H−インダゾール(500mg、1.2mmol)を含むTHF(10mL)に、塩化アンモニウム(800mg、15mmol)を含む水(3mL)および亜鉛末(650mg、9.9mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過した。化合物を、DCM(2*100mL)で抽出し、溶媒を蒸留して除去し、粗生成物を得た(300mg、67.2%)。LCMS:98.6%、m/z=374.3(M+1)
実施例11の工程7で記載されるのと同じ反応条件を用いて、(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−シクロプロピル−1H−インダゾール−6−アミン(300mg、0.8mmol)を2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(中間体4)(200mg、0.960mmol)と反応させた。これをさらにメタノール性HClで処理し、標題化合物を得た(100mg、61.3%)。
1HNMR (CD3OD、400MHz): δ 8.99 (s, 1H), 8.91 (d, 1H), 8.65 (s, 1H), 8.55 (d, 1H), 8.4−8.3 (bs, 1H), 8.12 (s, 1H), 8.0−7.9 (s, 1H), 4.74 (s, 1H), 3.90−3.85 (m, 2H), 3.73−3.69 (m, 2H), 2.93 (s, 3H), 2.50−2.30 (m, 2H), 1.28−1.18 (m, 4H). LCMS: 99.56%, m/z = 445.2 (M+1).HPLC: 97.67%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(1,2,3,6−テトラヒドロピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (DMSO−d6、400MHz): δ10.25 (s, 1H), 9.37 (s, 1H), 8.98 (s, 1H), 8.44 (s, 1H), 7.39 (s, 1H), 7.68 (s, 1H), 6.81 (s, 1H), 4.50−4.45 (m, 1H), 3.85−3.81 (m, 3H), 3.43−3.16 (m, 4H), 3.10−2.70 (m, 6H), 2.33−2.50 (m, 2H), 1.90−1.85 (m, 1H). LCMS: 98.6%, m/z = 409.3 (M+1). HPLC: 91.38%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリミジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (DMSO−d6、400MHz): δ 10.39 (s, 1H), 9.10 (s, 1H), 8.96 (d, 1H), 8.46 (s, 1H), 8.04 (d, 1H), 7.90 (s, 1H), 7.64 (s, 1H), 5.10 (bs, 1H), 4.55−4.50 (m, 1H), 3.98 (s, 3H), 3.32−3.10 (m, 2H), 3.01−2.92 (m, 2H), 2.92 (s, 3H), 2.34−2.30 (m, 1H), 1.95−1.90 (m, 1H). LCMS: 90.12%, m/z = 420.3 (M+1). HPLC: 98.74%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−4−メチル−2−(2−メチルピリミジン−4−イル)オキサゾール−5−カルボキサミド塩酸塩
1HNMR (DMSO−d6、300MHz): δ 10.07 (s, 1H), 8.65 (d, 1H),8.37 (s, 1H), 7.97 (s, 1H), 7.90−7.85 (m, 2H), 7.60 (s, 1H), 5.12 (s, 1H), 4.50−4.45 (m, 1H), 3.98 (s, 3H), 3.21−3.16 (m, 3H), 3.02−3.92 (m, 3H), 2.58 (s, 3H), 2.55 (s, 3H). LCMS: 98.34%, m/z = 432.9 (M+1). HPLC: 99.55%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(ピペリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
実施例11の工程7で記載されるのと同じ反応条件を用いて、2−(1−(tert−ブトキシカルボニル)−1,2,3,6−テトラヒドロピリジン−4−イル)オキサゾール−4−カルボン酸(中間体10、工程2)(100mg、0.387mmol)を(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−1H−インダゾール−6−アミン(134mg、0.387mmol)と反応させ、標題化合物を得た(200mg、82.9%)。LCMS:98.34%、m/z=623.1(M+1)。
tert−ブチル(S)−4−(4−((5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)カルバモイル)オキサゾール−2−イル)−3,6−ジヒドロピリジン−1(2H)−カルボキシレート(中間体10、工程2)(75mg、0.12mmol)を含むエタノール(5mL)の溶液を、10%Pd/cを用いてH2バルーン圧の存在下で12時間の間水素化した。反応の完了後、触媒をセライト(登録商標)に通して濾過し、濃縮し、粗生成物を得た(60mg)。LCMS:94.19%、m/z=625.5(M+1)。
tert−ブチル(S)−4−(4−((5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)カルバモイル)オキサゾール−2−イル)ピペリジン−1−カルボキシレート(60mg、0.096mmol)を含むMeOH(1mL)の溶液、および1,4−ジオキサン.HCl(1mL)を添加し、反応混合物を1時間の間室温で撹拌した。反応の完了後、減圧下で濃縮し、ジエチルエーテルで洗浄し、標題化合物を得た(23mg、46.0%)。
1HNMR (DMSO−d6、400MHz): δ 10.18 (s, 1H), 8.25 (s, 1H), 8.43 (s, 1H), 7.93 (s, 1H), 7.69 (s, 1H), 4.48 (s, 1H), 3.99 (s, 3H), 3.40−3.20 (m, 5H), 3.16 (s, 2H), 3.10−2.85 (m, 4H), 2.25−2.20 (3H), 2.10−1.80 (m, 3H). LCMS: 100%, m/z = 410.8 (M+1). HPLC: 92.35%.
N−(5−(3−ヒドロキシ−8−アザビシクロ[3.2.1]オクタン−8−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (CDCl3、400MHz): δ 10.48 (s, 1H), 8.68 (d, 2H), 8.43 (s, 1H), 7.84 (s, 1H), 7.74 (s, 1H), 7.66 (d, 1H), 7.30 (s, 1H), 4.42 (s, 1H), 4.06 (s, 3H), 3.66 (bs, 2H), 2.80−2.75 (m, 3H), 2.67 (s, 3H), 2.40−2.35 (m, 3H), 2.20−2.15 (m, 2H), 2.01 (d, 1H). LCMS: 98.77%, m/z = 459.25 (M+1). HPLC: 98.76%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−5−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ 10.20 (s, 1H), 8.68 (d, 1H), 8.22 (d, 2H), 7.98 (s, 1H), 7.93−7.89 (m, 2H), 7.54 (s, 1H), 5.12 (s, 1H), 4.45−4.40 (m, 1H), 4.00 (s, 3H), 3.22−3.19 (m, 2H), 3.04 (d, 2H), 2.61 (s, 3H), 2.33−2.25 (m, 1H), 1.95−1.90 (m, 1H). LCMS: 97.94%, m/z = 419.0 (M+1). HPLC: 95.09%.
N−(5−(4−ヒドロキシ−4−(ヒドロキシメチル)ピペリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド
1HNMR (DMSO−d6、400MHz): δ10.54 (s, 1H), 9.19 (s, 1H), 8.78 (d, 1H), 8.54 (s, 1H), 8.24 (d, 1H), 8.19 (s, 1H), 7.90 (s, 1H), 7.63 (s, 1H), 3.96 (s, 3H), 3.36−3.30 (m, 3H), 3.12−3.00 (m, 2H), 2.80−2.70 (m, 5H), 2.15−2.05 (m, 2H), 1.60−1.50 (m, 2H). LCMS: 99.00%, m/z = 463.25 (M+1). HPLC: 95.03%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)−5−メチル−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CDCl3、300MHz): δ 10.53 (s, 1H), 8.67 (d, 1H), 8.61 (s, 1H), 7.87 (s, 1H), 7.83 (s, 1H), 7.75 (d, 1H), 7.55 (s, 1H), 4.65−4.55 (m, 1H), 4.08 (s, 3H), 3.43−3.39 (m, 1H), 3.25 (d, 1H), 3.14 (dd, 1H), 2.97 (q, 1H), 2.86 (s, 3H), 2.67 (s, 3H), 2.65−2.60 (m, 1H), 2.60−2.50 (m, 1H), 2.20−2.10 (m, 1H). LCMS: 99.58%, m/z = 432.9 (M+1). HPLC: 96.85%.
(S)−2−(2−エチルピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CD3OD、400MHz): δ 8.62 (s, 1H), 8.53 (d, 1H), 8.44 (s, 1H), 7.92 (brs, 1H), 7.83 − 7.79 (m, 2H), 7.58 (s, 1H), 4.67− 4.63 (m, 1H), 3.94 (s, 3H), 3.40−3.36 (m, 3H), 3.15−2.90 (m, 4H), 2.50−2.40 (m, 1H), 2.10−2.00 (m, 1H), 1.38−1.27 (m, 4H). LCMS: 91.71%, m/z = 433.1 (M+1). HPLC: 95.03%.
2−(2−アミノピリジン−4−イル)−N−(5−(4−(ヒドロキシメチル)ピペリジン−1−イル)−1,3−ジメチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド塩酸塩
実施例11の工程2で記載される同じ反応条件を用いて、無水酢酸(12.24g、120mmol)を、4−フルオロ−2−メチルアニリン(5.0g、40mmol)および酢酸カリウム(5g、52mmol)を含むクロロホルム(50ml)の混合物に徐々に添加し、60℃で1時間の間撹拌した。1時間後、反応混合物を再び室温まで冷却し、亜硝酸イソアミル(9.28g、80mmol)を添加し、さらに75℃まで一晩の間加熱した。反応混合物をDCMで希釈し、水およびブライン溶液で洗浄し、Na2SO4上で乾燥させ、蒸発させた。粗化合物をカラムクロマトグラフィーにより精製し、50%酢酸エチルを含むヘキサンを用いて溶離し、標題化合物を得た(1.8g、25.3%)。LCMS:m/z=178.0。
1−(5−フルオロ−1H−インダゾール−1−イル)エタン−1−オン(2.1g、11.8mmol)を含むメタノール(20ml)および濃塩酸(10ml)の混合物を50℃まで2時間の間加熱した。反応の完了後、反応混合物を減圧下で蒸発乾固させた。残渣を飽和重炭酸ナトリウム溶液で塩基性化し、酢酸エチルに抽出し、水で洗浄し、濃縮し、標題化合物を得た(1.6g、100%)。LCMS:95.9%;m/z=137.2。
N−ブロモスクシンイミド(2.09g、11.76mmol)を数回に分けて、5−フルオロ−1H−インダゾール(1.6g、11.76mmol)の溶液に0℃で添加し、その後、室温で2時間の間撹拌した。反応の完了後、反応混合物をDCMで希釈し、水で洗浄し、濃縮し、標題化合物を得た(1.5g、59.3%)。LCMS:95.6%;m/z=214.9
3−ブロモ−5−フルオロ−1H−インダゾール(1.2g、5.63mmol)を数回に分けて、冷却し、かつ撹拌したニトロ化混合物(5ml硫酸+5ml硝酸)に−10℃で添加し、その後室温で3時間の間撹拌した。反応の完了後、反応混合物を、砕氷上で反応停止させ、黄色固体を濾過し、乾燥させ、標題化合物を得た(800mg、55.05%)。LCMS:82.7%;m/z=259.95
メタンスルホニルクロリド(424mg、3.72mmol)を3−ブロモ−6−ニトロ−1H−インダゾール−5−オール(800mg、3.1mmol)を含むDCMおよびトリエチルアミン(1.3ml、9.3mmol)の混合物に0℃で添加し、その後、室温で2時間の間撹拌した。反応の完了後、反応混合物をDCMで希釈し、水で洗浄し、濃縮し、標題化合物を得た(1.0g、80.1%)。
(ピペリジン−4−イル)メタノール(513mg、4.464mmol)を3−ブロモ−6−ニトロ−1H−インダゾール−5−イルメタンスルホナート(1g、2.976mmol)および炭酸カリウム(1.23g、8.928mmol)を含むDMF(10ml)の混合物に、0℃で添加し、その後室温で16時間の間撹拌した。反応の完了後、反応混合物を氷水上に注ぎ、酢酸エチルで抽出し、濃縮し、標題化合物を得た(1.2g粗、100%)。LCMS:84.7%、m/z=355.0(M+1)
TBDMS塩化物(606mg、4.04mmol)を(1−(3−ブロモ−6−ニトロ−1H−インダゾール−5−イル)ピペリジン−4−イル)メタノール(1.2g、3.3mmol)およびイミダゾール(673mg、9.9mmol)を含むDMFの冷却混合物に0℃で添加し、その後室温で6時間の間撹拌した。反応混合物を氷水上に注ぎ、酢酸エチルに抽出し、濃縮した。粗化合物をシリカゲルカラムクロマトグラフィーにより精製し、0−20%酢酸エチルを含むヘキサンを用いて溶離し、標題化合物を得た(1.5g、96%)。LCMS:90.38%、m/z=471.5(M+1)
水素化ナトリウム(84.8mg、2.12mmol)を含むDMF(5mL)の溶液に、3−ブロモ−5−(4−(((tert−ブチルジメチルシリル)オキシ)メチル)ピペリジン−1−イル)−6−ニトロ−1H−インダゾール(800mg、1.72mmol)を0℃で添加した。15分後、その溶液に0℃でヨウ化メチル(365mg、2.59mmol)を添加した。反応混合物を2時間の間室温にさせた。反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをシリカゲルカラムクロマトグラフィーにより精製し、20%酢酸エチルを含むヘキサンを用いて溶離し、標題化合物を得た(800mg、97%)。LCMS:98.7%、m/z=485.0(M+1)
3−ブロモ−5−(4−(((tert−ブチルジメチルシリル)オキシ)メチル)ピペリジン−1−イル)−1−メチル−6−ニトロ−1H−インダゾール(800mg、1.652mmol)、メチルボロン酸(146mg、2.48mmol)、トリシクロヘキシルホスフィン(92mg、0.33mmol)、酢酸パラジウム(37mg、0.165mmol)、リン酸三カリウム(1.05g、4.956mmol)を含むトルエン(10ml)および水(2ml)の溶液を、封管中で110℃にて一晩の間加熱した。反応後、反応混合物を酢酸エチルで希釈し、セライト(登録商標)上で濾過し、濾液を濃縮した。粗化合物をシリカゲルカラムクロマトグラフィー上で精製し、30%酢酸エチルを含むヘキサンを用いて溶離し、標題化合物を得た(600mg、86%)。LCMS:95.9%、m/z=419.4(M+1)
5−(4−(((tert−ブチルジメチルシリル)オキシ)メチル)ピペリジン−1−イル)−1,3−ジメチル−6−ニトロ−1H−インダゾール(600mg、1.43mmol)を含むTHF(12mL)の溶液に塩化アンモニウム(757mg、14.3mmol)を含む水(3mL)および亜鉛末(466mg、7.17mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過した。化合物を、DCM(2*100mL)で抽出し、溶媒を蒸留して除去し、粗生成物を得た(360mg、64.9%)。LCMS:96.4%、m/z=390.2(M+1)
実施例11の工程7で記載される同じ反応条件を用いて、5−(4−(((tert−ブチルジメチルシリル)オキシ)メチル)ピペリジン−1−イル)−1,3−ジメチル−1H−インダゾール−6−アミン(150mg、0.386mmol)を含むDMF(3mL)を2−(2−アミノピリジン−4−イル)オキサゾール−4−カルボン酸(93.7mg、0.464mmol)と反応させた。これをその後、メタノール性HClで処理し、標題化合物を得た(45mg、46.8%)
1HNMR (CDCl3、400MHz): δ 9.32 (s, 1H), 8.41 (s,1H), 8.23 (d, 1H), 7.30−7.25 (m, 3H), 7.19 (d, 1H), 4.81 (s, 2H), 3.96 (s, 3H), 3.56 (d, 2H), 3.01 (d, 2H), 2.78 (t, 2H), 2.59 (s, 3H), 1.70−1.60 (m, 4H). LCMS: 100%, m/z = 462.1 (M+1). HPLC: 98.67%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−(ピペリジン−4−イルメチル)−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
(S)−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例11の工程4)(800mg、2.209mmol)を含むDMF(5mL)の溶液に、K2CO3(618mg、4.419mmol)を0℃で添加した。15分後、0℃で、tert−ブチル4−(ブロモメチル)ピペリジン−1−カルボキシレート(730mg、2.651mmol)を添加した。反応混合物を、100℃まで12時間の間加熱した。反応混合物を、水で反応停止させ、EtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをシリカゲルカラムクロマトグラフィーにより精製し、20%酢酸エチルを含むヘキサンで溶離して、異性体A tert−ブチル(S)−4−((5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール−1−イル)メチル)ピペリジン−1−カルボキシレートを得た(630mg、51.2%)。LCMS:97.8%、m/z=560.2(M+1)。
tert−ブチル(S)−4−((5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−6−ニトロ−1H−インダゾール−1−イル)メチル)ピペリジン−1−カルボキシレート(実施例44の工程1異性体−Bの生成物)(630mg、1.125mmol)を含むTHF(10mL)の溶液に、塩化アンモニウム(0962mg、18.0mmol)を含む水(2mL)および亜鉛末(588mg、9.0mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過した。化合物を、酢酸エチルで抽出し、溶媒を蒸留して除去し、標題化合物を得た(450mg、96.2%)。LCMS:97.1%、m/z=530.3(M+1)。
実施例11の工程7で記載される同じ反応条件を用いて、tert−ブチル(S)−4−((6−アミノ−5−(3−((tert−ブチルジメチルシリル)オキシ)ピロリジン−1−イル)−1H−インダゾール−1−イル)メチル)ピペリジン−1−カルボキシレート(450mg、0.0.85mmol)を、2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(260mg、0.1.27mmol)と反応させた。これをその後、メタノール性HClで処理し、標題化合物を得た(200mg、67.56%)。
1HNMR (DMSO−d6、400MHz): δ 10.42 (s, 1H), 9.05 (s, 1H), 8.68 (d, 1H), 8.54 (s, 1H), 7.98 (s, 1H), 7.92 (s, 1H), 7.80 (d, 1H), 7.68 (s, 1H), 5.14 (d, 1H), 4.60−4.50 (m, 1H), 4.27 (d, 2H), 3.36−3.21 (m, 6H), 3.02−2.97 (m, 2H), 2.83 (t, 2H), 2.59 (s, 3H), 2.36−2.31 (m, 1H), 2.25−2.15 (m, 1H), 1.70−1.60 (m, 2H), 1.50−1.40 (m, 2H).LCMS: 98.9%, m/z = 502.5 (M+1). HPLC: 98.56%.
N−(5−(4−(ヒドロキシメチル)ピペリジン−1−イル)−1,3−ジメチル−1H−インダゾール−6−イル)−2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボキサミド塩酸塩
実施例11の工程7で記載される同じ反応条件を用いて、5−(4−(((tert−ブチルジメチルシリル)オキシ)メチル)ピペリジン−1−イル)−1,3−ジメチル−1H−インダゾール−6−アミン(工程10、実施例43)(150mg、0.386mmol)を含むDMF(3mL)を2−(2−メチルピリジン−4−イル)オキサゾール−4−カルボン酸(中間体4)(93.7mg、0.464mmol)と反応させた。これをその後、メタノール性HClで処理し、標題化合物を得た(90mg、78.2%)。
1HNMR (CDCl3、400MHz): δ 9.26 (s, 1H), 8.70 (d,1H), 8.46 (s, 1H), 7.86 (s, 1H), 7.79 (d, 1H), 7.30 (s, 1H), 7.22 (d, 1H), 3.98 (s, 3H), 3.55−3.50 (m, 2H), 3.02 (d, 2H), 2.78 (t, 2H), 2.70 (s, 3H), 2.59 (s, 3H), 1.80−1.70 (m, 2H) 1.50−1.35 (m, 3H). LCMS: 100%, m/z = 462.0 (M+1). HPLC: 98.23%.
(S)−2−(2−シクロプロピルピリジン−4−イル)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)オキサゾール−4−カルボキサミド塩酸塩
1HNMR (CD3OD、300MHz): δ 8.71 (s, 1H), 8.57−8.54 (m, 2H), 7.94−7.90 (m, 2H), 7.82 (dd, 1H), 7.68 (s, 1H), 4.70−4.60 (m, 1H), 4.04 (s, 3H), 3.12−3.03 (m, 5H), 2.50−2.40 (m, 1H), 2.30−2.00 (m, 1H), 1.15−1.05 (m, 4H). LCMS: 96.42%, m/z = 444.9 (M+1). HPLC: 97.93%.
N−(5−(4−ヒドロキシピペリジン−1−イル)−2−メチル−2H−インダゾール−6−イル)ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド塩酸塩
実施例11の工程5で記載されるのと同じ反応条件を用いて、水素化ナトリウム(152mg、3.79mmol)を含むTHF(20mL)に、5−(4−((tert−ブチルジメチルシリル)オキシ)ピペリジン−1−イル)−6−ニトロ−1H−インダゾール(実施例17の工程3の生成物)(680mg、1.80mmol)を0℃で添加した。15分後、0℃で、ヨウ化メチル(1.02g、7.21mmol)を添加した。反応混合物を2時間の間室温にさせた。反応混合物をEtOAcで希釈し、ブラインで洗浄し、無水Na2SO4上で乾燥させた。これをシリカゲルカラムクロマトグラフィーにより精製し、15%酢酸エチルを含むヘキサンを用いて溶離し、標題化合物を得た(395mg、56%)。LCMS:40.0%、m/z=391.2(M+1)。
実施例11の工程6で記載されるのと同じ反応条件を用いて、5−(4−((tert−ブチルジメチルシリル)オキシ)ピペリジン−1−イル)−2−メチル−6−ニトロ−2H−インダゾール(工程1実施例47の生成物)(400mg、1.024mmol)を含むTHF(20mL)に、塩化アンモニウム(490mg、8.19mmol)を含む水(10mL)および亜鉛末(532mg、8.19mmol)を添加し、室温で30分間撹拌した。触媒をセライト(登録商標)に通して濾過した。化合物を、酢酸エチルで抽出し、溶媒を蒸留して除去し、生成物を得た(232mg、65.0%)。LCMS:97.7%、m/z=361.1(M+1)。
実施例11の工程6で記載されるのと同じ反応条件を用いて、5−(4−((tert−ブチルジメチルシリル)オキシ)ピペリジン−1−イル)−2−メチル−2H−インダゾール−6−アミン(110mg、0.306mmol)を、ピラゾロ[1,5−a]ピリミジン−3−カルボン酸(50mg、0.306mmol)と反応させた。これをその後、メタノール性HClで処理し、標題化合物を得た(39mg、34%)。
1HNMR (CD3OD、300MHz): δ 9.13 (dd, 1H), 9.00−8.96 (bs, 1H), 8.78 (s, 1H), 8.70 (s, 1H), 8.05 (s, 1H), 7.55 (s, 1H), 7.30−7.26 (m, 1H), 4.15 (s, 3H), 3.15−3.05 (m, 3H), 2.90−2.80 (m, 2H), 2.10−2.00 (m, 4H). LCMS: 100%, m/z = 392.2 (M+1). HPLC: 98.65%.
(S)−N−(5−(3−ヒドロキシピロリジン−1−イル)−1−メチル−1H−インダゾール−6−イル)ピラゾロ[1,5−a]ピリミジン−3−カルボキサミド塩酸塩
1HNMR (DMSO−d6、400MHz): δ 10.89 (s, 1H), 9.38 (d, 1H), 8.90 (d, 1H), 8.73 (s,1H), 8.67 (s, 1H), 7.90 (s, 1H), 7.65 (s, 1H), 7.37−7.34 (m, 1H) 4.55−4.50 (m, 1H), 3.98 (s, 3H), 3.47 (t, 1H), 3.22 (q, 1H), 3.10−3.00 (m, 2H), 2.84 (dd, 1H), 2.35−2.25 (m, 2H), 1.95−1.85 (m, 1H). LCMS: 98.9%, m/z = 378.0 (M+1). HPLC: 96.63%.
化合物を、それらのIRAK−4酵素を阻害する能力に対し、TR−FRETアッセイにおいて、Millipore、USAからの組換えIRAK−4キナーゼを用いて試験した。アッセイ緩衝液は50mM Tris−HCl pH7.5、20mM MgCl2、1mM EGTA、2mM DTT、3mM MnCl2および0.01%Tweenとし、20.5ngのIRAK−4キナーゼをアッセイのために使用した。酵素の試験化合物との30分間の室温でのプレインキュベーション後、100nMビオチンヒストンH3(Millipore、USA)および20μM ATP(Sigma、USA)を含む基質混合物を添加し、反応物を30分間インキュベートした。インキュベーション後、反応を、40mM EDTA、1nMのユーロピウム−抗−ホスホ−ヒストンH3(Ser10)抗体(Perkin Elmer、USA)および20nM SureLightアロフィコシアニン−ストレプトアビジン(Perkin Elmer、USA)を含む停止混合物の添加により停止させた。615nmおよび665nmでの蛍光発光を340nmの励起で測定し、パーセント阻害を蛍光強度の比[(F665/F615)×10000]から推定した。化合物を最初に1μMおよび10μM濃度でスクリーニングし、強力な化合物(1μMで>50%阻害)を用量応答研究に供した。IC50値を、用量−応答データをシグモイド用量応答(可変勾配)、Graphpad Prismソフトウェアバージョン6.01を使用するカーブフィッティングプログラムにフィッティングすることにより、推定した。
Claims (26)
- 式(I)の化合物:
(式中、
Z1は任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリルであり、または存在せず;
Z2は任意で置換されたシクロアルキル、アリールまたはヘテロシクリルであり;
R1は水素、任意で置換されたアルキル、アミノ、ハロゲン、シアノ、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R2は、各事象において、水素、ハロゲン、アミノ、任意で置換されたアルキル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
R3は、各事象において、ヒドロキシル、ハロゲン、任意で置換されたアルキル、任意で置換されたアルコキシ、任意で置換されたシクロアルキルまたは−NRaRbであり;
RaおよびRbは、独立して各事象に対し、水素、任意で置換されたアルキル、任意で置換されたアシル、任意で置換されたシクロアルキル、任意で置換されたアリール、任意で置換されたヘテロシクリル、任意で置換されたアリールアルキルまたは任意で置換されたヘテロシクリルアルキルであり;
mは、各事象において、0、1または2であり;ならびに
nは、各事象において、0、1、または2である)。 - Z1はテトラゾリル、チエニル、トリアゾリル、ピロリル、ピリジル、ピラニル、ピラジニル、ピリダジニル、ピリミジル、イミダゾリル、オキサジアゾリル、チアジアゾリル、チアゾリル、イソチアゾリル、オキサゾリル、フラニル、ピラゾリル、ベンズイソキサゾリル、ベンゾチアゾリル、ベンゾフラニル、ベンゾチエニル、ベンゾトリアジニル、フタラジニル、チアントレン、ジベンゾフラニル、ジベンゾチエニル、ベンズイミダゾリル、インドリル、イソインドリル、インダゾリル、キノリニル、イソキノリニル、キナゾリニル、キノキサリニル、プリニル、プテリジニル、9H−カルバゾリル、α−カルボリン、インドリジニル、ベンゾイソチアゾリル、ベンゾキサゾリル、ピロロピリジル、フロピリジニル、プリニル、ベンゾチアジアゾリル、ベンゾオキサジアゾリル、ベンゾトリアゾリル、ベンゾトリアジアゾリル、カルバゾリル、ジベンゾチエニル、アクリジニルおよびピラゾロピリミジルである、請求項1に記載の式(I)の化合物またはその薬学的に許容される塩。
- Z2はアゼチジニル、オキセタニル、イミダゾリジニル、ピロリジニル、オキサゾリジニル、チアゾリジニル、ピラゾリジニル、テトラヒドロフラニル、ピペリジニル、ピペラジニル、テトラヒドロピラニル、モルホリニル、チオモルホリニル、1,4−ジオキサニル、テトラゾリル、チエニル、トリアゾリル、ピロリル、ピリジニル、テトラヒドロピリジニル、ピラニル、ピラジニル、ピリダジニル、ピリミジル、ピペラジニル、イミダゾリル、オキサジアゾリル、チアジアゾリル、チアゾリル、イソチアゾリル、オキサゾリル、フラニルピラゾリル、インドリニル、インドリニルメチル、2−アザ−ビシクロ[2.2.2]オクタニル、クロマニル、キサンテニルまたはピロロピリジルである、請求項1に記載の式(I)の化合物またはその薬学的に許容される塩。
- Z2はピロリジニル、ピペリジニル、ピペラジニル、ピリジニル、ピリミジル、テトラヒドロピリジニルまたはピロロピリジルである、請求項1〜5のいずれか一項に記載の式(I)の化合物。
- R1は、ヘテロシクリルであり;ハロゲン、ヒドロキシルまたはヒドロキシアルキルにより任意で置換される、請求項1〜5のいずれか一項に記載の化合物。
- R1は任意で置換されたアゼチジニル、ピペリジニル、モルホリニル、ピロリジニルまたはアザビシクロオクタニルである、請求項7に記載の化合物。
- R2は、ヘテロシクリルにより任意で置換されたアルキルである、請求項1〜4のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- R2は水素である、請求項1〜4のいずれか一項に記載の化合物、またはその薬学的に許容される塩。
- R2はシクロプロピルである、請求項1〜4のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- R3はハロゲン、アルキル、ハロアルキル、−NRaRb、シクロアルキル、ヒドロキシルまたはヒドロキシアルキルであり;ならびにRaおよびRbは、請求項1で規定される通りである、請求項1〜5のいずれか一項に記載の化合物またはその薬学的に許容される塩。
- 請求項1〜13のいずれか一項に記載の少なくとも1つの化合物、またはその薬学的に許容される塩もしくは立体異性体、および薬学的に許容される担体または賦形剤を含む医薬組成物。
- 薬として使用するための、請求項1〜13のいずれか一項に記載の化合物、またはその薬学的に許容される塩もしくは立体異性体。
- 治療的有効量の、請求項1〜13のいずれか一項に記載の化合物を投与することを含む、被験体においてIRAK4媒介障害または疾患または病状を治療する方法。
- 前記IRAK4媒介障害または疾患または病状は、癌、炎症性障害、自己免疫疾患、代謝障害、遺伝性障害、ホルモン関連疾患、免疫不全障害、細胞死と関連する病状、破壊性骨障害、トロンビン誘発性血小板凝集、肝疾患および心血管障害からなる群より選択される、請求項16に記載の方法。
- 前記癌は、脳、腎臓、肝臓、胃、腟、卵巣、胃腫瘍、乳房、膀胱結腸、前立腺、膵臓、肺、子宮頸部、精巣、皮膚、骨または甲状腺の固形腫瘍、良性または悪性腫瘍、癌腫;肉腫、神経膠芽腫、神経芽細胞腫、多発性骨髄腫、胃腸癌、頭頸部の腫瘍、上皮過剰増殖、乾癬、前立腺過形成、新生物、腺腫、腺がん、ケラトアカントーマ、類表皮がん、大細胞がん、非小細胞肺がん、リンパ腫、ホジキンおよび非ホジキン、乳がん、濾胞がん、乳頭がん、精上皮腫、メラノーマ;白血病、びまん性大細胞型B細胞リンパ腫(DLBCL)、活性化B細胞様DLBCL、慢性リンパ性白血病(CLL)、慢性リンパ球性リンパ腫、原発性体液性リンパ腫、バーキットリンパ腫/白血病、急性リンパ性白血病、B細胞性前リンパ性白血病、リンパ形質細胞性リンパ腫、ワルデンストレーム高ガンマグロブリン血症(WM)、脾臓周辺帯リンパ腫、血管内大細胞型B細胞リンパ腫、形質細胞腫および多発性骨髄腫から選択される血液悪性腫瘍からなる群より選択される、請求項17に記載の方法。
- 前記炎症性障害は、眼アレルギー、結膜炎、乾性角結膜炎、春季カタル、アレルギー性鼻炎、自己免疫性血液疾患(例えば溶血性貧血、再生不良性貧血、真正赤血球性貧血および特発性血小板減少症)、全身性エリテマトーデス、関節リウマチ、多発性軟骨炎、強皮症、ウェゲナー肉芽腫症、皮膚筋炎、慢性活動性肝炎、重症筋無力症、スティーブンス・ジョンソン症候群、特発性スプルー、自己免疫性炎症性腸疾患(例えば潰瘍性大腸炎およびクローン病)、過敏性腸症候群、セリアック病、歯周炎、肺硝子膜症、腎臓疾患、糸球体疾患、アルコール性肝疾患、多発性硬化症、内分泌眼疾患、グレーブス病、サルコイドーシス、肺胞炎、慢性過敏性肺炎、原発性胆汁性肝硬変、ぶどう膜炎(前部および後部)、シェーグレン症候群、間質性肺線維症、乾癬性関節炎、全身性若年性特発性関節炎、腎炎、血管炎、憩室炎、間質性膀胱炎、糸球体腎炎(例えば、特発性ネフローゼ症候群または微小変化型ネフローゼを含む)、慢性肉芽腫性疾患、子宮内膜症、レプトスピラ症腎疾患、緑内障、網膜疾患、頭痛、疼痛、複合性局所疼痛症候群、心肥大、筋消耗、異化障害、肥満、胎児発育遅延、高コレステロール血症、心疾患、慢性心不全、中皮腫、無汗性外胚葉形成不全、ベーチェット病、色素失調症、パジェット病、膵炎、遺伝性周期性発熱症候群、喘息、急性肺損傷、急性呼吸促迫症候群、好酸球増加症、過敏症、アナフィラキシー、結合織炎、胃炎、胃腸炎、副鼻腔炎、眼アレルギー、シリカ誘発疾患、慢性閉塞性肺疾患(COPD)、嚢胞性線維症、酸誘発性肺損傷、肺高血圧、多発ニューロパチー、白内障、全身性硬化症に伴う筋肉の炎症、封入体筋炎、重症筋無力症、甲状腺炎、アジソン病、扁平苔癬、虫垂炎、アトピー性皮膚炎、喘息、アレルギー、眼瞼炎、細気管支炎、気管支炎、滑液包炎、子宮頸管炎、胆管炎、胆嚢炎、慢性移植片拒絶、大腸炎、結膜炎、膀胱炎、涙腺炎、皮膚炎、若年性関節リウマチ、皮膚筋炎、脳炎、心内膜炎、子宮内膜炎、腸炎、小腸結腸炎、上顆炎、精巣上体炎、筋膜炎、ヘノッホ・シェーンライン紫斑病、肝炎、化膿性汗腺炎、免疫グロブリンA腎症、間質性肺疾患、喉頭炎、乳腺炎、髄膜炎、脊髄炎心筋炎、筋炎、腎炎、卵巣炎、精巣炎、骨炎、耳炎、膵炎、耳下腺炎、心膜炎、腹膜炎、咽頭炎、胸膜炎、静脈炎、間質性肺炎、肺炎、多発性筋炎、直腸炎、前立腺炎、腎盂腎炎、鼻炎、卵管炎、副鼻腔炎、口内炎、滑膜炎、腱炎、扁桃炎、潰瘍性大腸炎、血管炎、外陰炎、円形脱毛症、多形性紅斑、疱疹状皮膚炎、強皮症、白斑、過敏性血管炎、蕁麻疹、水疱性類天疱瘡、尋常性天疱瘡、落葉状天疱瘡、腫瘍随伴性天疱瘡、後天性表皮水疱症、急性および慢性痛風、慢性痛風関節炎、乾癬、乾癬性関節炎、関節リウマチ、クリオピリン関連周期性症候群(CAPS)および変形性関節症からなる群より選択される、請求項17に記載の方法。
- 癌、炎症性障害、自己免疫疾患、代謝障害、遺伝性障害、ホルモン関連疾患、免疫不全障害、細胞死と関連する病状、破壊性骨障害、トロンビン誘発性血小板凝集、肝疾患および心血管障害の治療のために使用するための、請求項1〜13のいずれか一項に記載の化合物、またはその薬学的に許容される塩もしくは立体異性体。
- 癌、炎症性障害、自己免疫疾患、代謝障害、遺伝性障害、ホルモン関連疾患、免疫不全障害、細胞死と関連する病状、破壊性骨障害、トロンビン誘発性血小板凝集、肝疾患および心血管障害の治療のための薬の製造における、請求項1〜13のいずれか一項に記載の化合物、またはその薬学的に許容される塩もしくは立体異性体の使用。
- その必要がある被験体に、治療的有効量の、請求項1〜13のいずれか一項に記載の化合物を投与することを含む、MYD88突然変異と関連する疾患または病状を治療する方法。
- 前記MYD88突然変異と関連する疾患または病状は、癌、炎症性障害、自己免疫疾患、代謝障害、遺伝性障害、ホルモン関連疾患、免疫不全障害、細胞死と関連する病状、破壊性骨障害、トロンビン誘発性血小板凝集、肝疾患および心血管障害からなる群より選択される、請求項22に記載の方法。
- 前記疾患または病状は潰瘍性大腸炎である、請求項22に記載の方法。
- 前記疾患または病状はリンパ腫である、請求項22に記載の方法。
- 前記疾患または病状はびまん性大細胞型B細胞リンパ腫およびワルデンストレームマクログロブリン血症から選択される癌である、請求項22に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN3017CH2014 | 2014-06-20 | ||
IN3017/CHE/2014 | 2014-06-20 | ||
PCT/IB2015/054620 WO2015193846A1 (en) | 2014-06-20 | 2015-06-19 | Substituted indazole compounds as irak4 inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017518348A true JP2017518348A (ja) | 2017-07-06 |
JP2017518348A5 JP2017518348A5 (ja) | 2018-08-02 |
Family
ID=54934936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016574004A Pending JP2017518348A (ja) | 2014-06-20 | 2015-06-19 | Irak4阻害剤としての置換インダゾール化合物 |
Country Status (16)
Country | Link |
---|---|
US (1) | US20170152263A1 (ja) |
EP (1) | EP3157521A4 (ja) |
JP (1) | JP2017518348A (ja) |
KR (1) | KR20170016500A (ja) |
CN (1) | CN106456609A (ja) |
AU (1) | AU2015275730A1 (ja) |
BR (1) | BR112016029853A2 (ja) |
CA (1) | CA2952188A1 (ja) |
CU (1) | CU20160188A7 (ja) |
EA (1) | EA201692418A1 (ja) |
HK (1) | HK1231411A1 (ja) |
IL (1) | IL249345A0 (ja) |
MX (1) | MX2016017147A (ja) |
PH (1) | PH12016502382A1 (ja) |
SG (1) | SG11201610009XA (ja) |
WO (1) | WO2015193846A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019503357A (ja) * | 2015-12-22 | 2019-02-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE052252T2 (hu) | 2014-01-13 | 2021-04-28 | Aurigene Discovery Tech Ltd | Eljárás IRAK4 inhibitorként rák kezelésére alkalmas oxazolo[4,5-b]piridin és tiazolo[4,5-b]piridin származékok elõállítására |
JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
CA2984259C (en) | 2015-04-30 | 2024-02-13 | Bayer Pharma Aktiengesellschaft | Combinations of inhibitors of irak4 with inhibitors of btk |
EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
EP3322698A4 (en) * | 2015-07-15 | 2019-01-09 | Aurigene Discovery Technologies Limited | INDAZOL AND AZAINDAZONE COMPOUNDS AS IRAQ-4 INHIBITORS |
US10435396B2 (en) | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
MX2018014897A (es) * | 2016-06-01 | 2019-04-24 | Bayer Pharma AG | Uso de indazoles 2-sustituidos para el tratamiento y la profilaxis de trastornos autoinmunes. |
IL292977A (en) | 2016-09-09 | 2022-07-01 | Incyte Corp | Pyrazolopyridine derivatives as modulators of hpk1 and their use in cancer therapy |
US20180072741A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyrimidine compounds and uses thereof |
WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
CN109890829B (zh) | 2016-11-02 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 作为IRAK4调节剂的吡唑并[1,5a]嘧啶衍生物 |
WO2018152220A1 (en) | 2017-02-15 | 2018-08-23 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
RS64411B1 (sr) | 2017-03-31 | 2023-09-29 | Aurigene Oncology Ltd | Jedinjenja i kompozicije za lečenje hematoloških poremećaja |
WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
JP2020524691A (ja) | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
JP2020524692A (ja) * | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Irak4調節因子としてのベンゾフラン |
WO2019051199A1 (en) | 2017-09-08 | 2019-03-14 | Incyte Corporation | 6-CYANO-INDAZOLE COMPOUNDS AS HEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) MODULATORS |
WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
EP3684365A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND USES OF SUCH |
FI3704108T3 (fi) * | 2017-10-31 | 2024-05-23 | Curis Inc | Irak4-estäjä yhdistelmässä bcl-2-estäjän kanssa käytettäväksi syövän hoitoon |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
EP3731869A4 (en) | 2017-12-26 | 2021-09-22 | Kymera Therapeutics, Inc. | KINASES IRAQ DEGRADATION AGENTS AND THEIR USES |
WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
EP3752504A4 (en) | 2018-02-14 | 2021-06-09 | Dana Farber Cancer Institute, Inc. | COMPOUNDS DEGRADING THE IRAQ AND USES OF THESE LATEST |
US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
MX2020008656A (es) | 2018-02-20 | 2020-12-09 | Incyte Corp | Derivados de n-(fenil)-2-(fenil)pirimidina-4-carboxamida y compuestos relacionados como inhibidores de la cinasa de progenitores hematopoyeticos 1 (hpk1) para tratar el cancer. |
US10752635B2 (en) | 2018-02-20 | 2020-08-25 | Incyte Corporation | Indazole compounds and uses thereof |
EP3774797A1 (en) * | 2018-04-05 | 2021-02-17 | Merck Patent GmbH | Heteroaryl compounds as type ii irak inhibitors and uses hereof |
US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
CN110833559A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗急性肺损伤致肺纤维化的用途 |
US11897863B2 (en) | 2018-08-17 | 2024-02-13 | Zhejiang Hisun Pharmaceutical Co., Ltd. | Indazole amine derivative, preparation method therefor and medical use thereof |
WO2020048471A1 (zh) * | 2018-09-06 | 2020-03-12 | 浙江海正药业股份有限公司 | 7-取代吲唑类衍生物及其制备方法和其在医药上的用途 |
EP3856348B1 (en) | 2018-09-25 | 2024-01-03 | Incyte Corporation | Pyrazolo[4,3-d]pyrimidine compounds as alk2 and/or fgfr modulators |
MX2021006154A (es) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics Inc | Degradadores de cinasas asociadas al receptor de interleucina 1 (irak) y usos de los mismos. |
US20220267335A1 (en) * | 2019-07-18 | 2022-08-25 | Bristol-Myers Squibb Company | Pyrazolo[3,4-d]pyrrolo[1,2-b]pyridazinyl compounds useful as irak4 inhibitors |
US11066394B2 (en) | 2019-08-06 | 2021-07-20 | Incyte Corporation | Solid forms of an HPK1 inhibitor |
WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
JP2024500247A (ja) * | 2020-12-25 | 2024-01-05 | メッドシャイン ディスカバリー インコーポレイテッド | アミドオキサゾール系化合物 |
CN113402499B (zh) | 2021-06-21 | 2022-05-13 | 上海勋和医药科技有限公司 | 一种亚磺酰亚胺取代的吲唑类irak4激酶抑制剂、制备方法及用途 |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05506425A (ja) * | 1990-05-18 | 1993-09-22 | ヘキスト・アクチエンゲゼルシヤフト | イソオキサゾール−4−カルボキサミド類およびヒドロキシアルキリデンシアノアセトアミド類を含有する製剤 |
WO2004103954A1 (ja) * | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
JP2005517657A (ja) * | 2001-12-19 | 2005-06-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 二環式n−アリールアミド類 |
JP2006505511A (ja) * | 2002-07-17 | 2006-02-16 | アムジエン・インコーポレーテツド | 置換ベンジルアミン誘導体および使用方法 |
JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
JP2007525482A (ja) * | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
JP2008239617A (ja) * | 2007-02-27 | 2008-10-09 | Otsuka Pharmaceut Co Ltd | 医薬 |
JP2009526072A (ja) * | 2006-02-10 | 2009-07-16 | トランステック ファーマ,インコーポレイティド | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 |
JP2011511835A (ja) * | 2008-02-13 | 2011-04-14 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
JP2013507446A (ja) * | 2009-10-13 | 2013-03-04 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
WO2013059587A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013068458A1 (en) * | 2011-11-10 | 2013-05-16 | Ucb Pharma S.A. | Therapeutically active thiazolo-pyrimidine derivatives |
JP2013525453A (ja) * | 2010-04-30 | 2013-06-20 | メルク・シャープ・エンド・ドーム・コーポレイション | ホスホイノシチド依存性キナーゼ1(pdk1)阻害薬 |
JP2013525370A (ja) * | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ.ベー. | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
WO2015119998A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1181327A (en) * | 1915-08-10 | 1916-05-02 | Michael F Mcandrew | Basket construction and guard therefor. |
US1301085A (en) * | 1916-11-06 | 1919-04-15 | Charles R Hadley Company | Loose-leaf binder. |
DE10023486C1 (de) * | 2000-05-09 | 2002-03-14 | Schering Ag | Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel |
SI1618092T1 (sl) * | 2003-05-01 | 2010-11-30 | Bristol Myers Squibb Co | Aril substituirane pirazolamidne spojine uporabnekot kinazni inhibitorji |
NZ575410A (en) * | 2006-09-07 | 2012-03-30 | Biogen Idec Inc | 2-(1H-Indazol-3-ylamino)-1H-benzimidazole derivatives |
EP2170834B1 (en) * | 2007-07-16 | 2014-01-08 | AbbVie Inc. | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
US10160753B2 (en) * | 2014-01-10 | 2018-12-25 | Aurigene Discovery Technologies Limited | Indazole compounds as IRAK4 inhibitors |
-
2015
- 2015-06-19 CA CA2952188A patent/CA2952188A1/en not_active Abandoned
- 2015-06-19 KR KR1020177001487A patent/KR20170016500A/ko unknown
- 2015-06-19 CU CUP2016000188A patent/CU20160188A7/es unknown
- 2015-06-19 JP JP2016574004A patent/JP2017518348A/ja active Pending
- 2015-06-19 WO PCT/IB2015/054620 patent/WO2015193846A1/en active Application Filing
- 2015-06-19 EP EP15809538.0A patent/EP3157521A4/en not_active Withdrawn
- 2015-06-19 CN CN201580033142.0A patent/CN106456609A/zh active Pending
- 2015-06-19 US US15/320,111 patent/US20170152263A1/en not_active Abandoned
- 2015-06-19 EA EA201692418A patent/EA201692418A1/ru unknown
- 2015-06-19 MX MX2016017147A patent/MX2016017147A/es unknown
- 2015-06-19 AU AU2015275730A patent/AU2015275730A1/en not_active Abandoned
- 2015-06-19 BR BR112016029853A patent/BR112016029853A2/pt not_active IP Right Cessation
- 2015-06-19 SG SG11201610009XA patent/SG11201610009XA/en unknown
-
2016
- 2016-11-29 PH PH12016502382A patent/PH12016502382A1/en unknown
- 2016-12-01 IL IL249345A patent/IL249345A0/en unknown
-
2017
- 2017-05-24 HK HK17105243.5A patent/HK1231411A1/zh unknown
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05506425A (ja) * | 1990-05-18 | 1993-09-22 | ヘキスト・アクチエンゲゼルシヤフト | イソオキサゾール−4−カルボキサミド類およびヒドロキシアルキリデンシアノアセトアミド類を含有する製剤 |
JP2005517657A (ja) * | 2001-12-19 | 2005-06-16 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | 二環式n−アリールアミド類 |
JP2006505511A (ja) * | 2002-07-17 | 2006-02-16 | アムジエン・インコーポレーテツド | 置換ベンジルアミン誘導体および使用方法 |
WO2004103954A1 (ja) * | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
JP2006526660A (ja) * | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Vr1レセプターのモジュレーター |
JP2007525482A (ja) * | 2003-10-07 | 2007-09-06 | レノビス, インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
JP2009526072A (ja) * | 2006-02-10 | 2009-07-16 | トランステック ファーマ,インコーポレイティド | ベンゾアゾール誘導体、組成物、及びオーロラキナーゼ阻害剤としての使用方法 |
JP2008239617A (ja) * | 2007-02-27 | 2008-10-09 | Otsuka Pharmaceut Co Ltd | 医薬 |
JP2011511835A (ja) * | 2008-02-13 | 2011-04-14 | シージーアイ ファーマシューティカルズ,インコーポレーテッド | 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法 |
JP2013507446A (ja) * | 2009-10-13 | 2013-03-04 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
JP2013525370A (ja) * | 2010-04-22 | 2013-06-20 | ヤンセン ファーマシューティカ エヌ.ベー. | ケトヘキソキナーゼ阻害剤として有用なインダゾール化合物 |
JP2013525453A (ja) * | 2010-04-30 | 2013-06-20 | メルク・シャープ・エンド・ドーム・コーポレイション | ホスホイノシチド依存性キナーゼ1(pdk1)阻害薬 |
JP2013529647A (ja) * | 2010-06-24 | 2013-07-22 | ケモセントリックス,インコーポレイティド | C5aRアンタゴニスト |
WO2013059587A1 (en) * | 2011-10-20 | 2013-04-25 | Sirtris Pharmaceuticals, Inc. | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
WO2013068458A1 (en) * | 2011-11-10 | 2013-05-16 | Ucb Pharma S.A. | Therapeutically active thiazolo-pyrimidine derivatives |
WO2015119998A1 (en) * | 2014-02-06 | 2015-08-13 | Abbvie, Inc. | 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof |
JP2017505327A (ja) * | 2014-02-06 | 2017-02-16 | アッヴィ・インコーポレイテッド | 6−ヘテロアリールオキシ−および6−アリールオキシ−キノリン−2−カルボキシアミドならびにその使用 |
Non-Patent Citations (4)
Title |
---|
BIOORG. MED. CHEM. LETT., vol. 14, JPN6019005698, 2004, pages 6011 - 6016, ISSN: 0003980212 * |
BIOORG. MED. CHEM., vol. 12, JPN6019005696, 2004, pages 2115 - 2137, ISSN: 0003980211 * |
REGISTRY(STN)[ONLINE], JPN7019000449, 2011, ISSN: 0003980213 * |
REGISTRY(STN)[ONLINE], JPN7019000450, 2014, ISSN: 0003980214 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019503357A (ja) * | 2015-12-22 | 2019-02-07 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
Also Published As
Publication number | Publication date |
---|---|
BR112016029853A2 (pt) | 2017-08-22 |
CU20160188A7 (es) | 2017-06-05 |
WO2015193846A1 (en) | 2015-12-23 |
US20170152263A1 (en) | 2017-06-01 |
KR20170016500A (ko) | 2017-02-13 |
EP3157521A1 (en) | 2017-04-26 |
EP3157521A4 (en) | 2018-02-14 |
SG11201610009XA (en) | 2017-01-27 |
AU2015275730A1 (en) | 2016-12-15 |
IL249345A0 (en) | 2017-02-28 |
CN106456609A (zh) | 2017-02-22 |
PH12016502382A1 (en) | 2017-02-20 |
MX2016017147A (es) | 2017-06-07 |
HK1231411A1 (zh) | 2017-12-22 |
EA201692418A1 (ru) | 2017-04-28 |
CA2952188A1 (en) | 2015-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017518348A (ja) | Irak4阻害剤としての置換インダゾール化合物 | |
JP2018524372A (ja) | Irak−4阻害剤としてのインダゾール及びアザインダゾール化合物 | |
US10954243B2 (en) | Substituted heterocyclic inhibitors of PTPN11 | |
KR20180026537A (ko) | Irak-4 저해제로서 치환된 아자 화합물 | |
JP7010935B2 (ja) | Usp30の阻害剤としての活性を有するシアノ置換ヘテロ環 | |
TW201819386A (zh) | Shp2磷酸酶抑制劑及其使用方法 | |
US10988458B2 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
US20110189167A1 (en) | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases | |
CA2976741A1 (en) | 1-cyano-pyrrolidine compounds as usp30 inhibitors | |
CN114650868A (zh) | Helios的小分子降解剂及其使用方法 | |
ES2788449T3 (es) | Inhibidores de GLS1 para tratar enfermedades | |
TW201341386A (zh) | 唑並[1,5-a]嘧啶基化合物、包含其之組成物及其使用方法 | |
EA015488B1 (ru) | Содержащие диариловый эфир соединения мочевины | |
JP2012514044A (ja) | Rafキナーゼ阻害剤として有用なヘテロアリール化合物 | |
JP2008531679A (ja) | オキシトシンアンタゴニストとしての1,2,4−トリアゾール誘導体とその使用 | |
CA2899968A1 (en) | Substituted 2-aminopyridine protein kinase inhibitor | |
WO2019158070A1 (zh) | A2a和/或a2b受体拮抗剂 | |
US12018017B2 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20170310 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20170310 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20170313 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180619 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180619 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190226 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20191008 |